Cardiff Oncology (CRDF) 10-K 10 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Feb. 29, 2016	Jun. 30, 2015
Document and Entity Information
Entity Registrant Name	Trovagene, Inc.
Entity Central Index Key	1,213,037
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		29,757,810
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	Yes
Entity Current Reporting Status	Yes
Entity Public Float			$ 195,681,564

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 67,493,047	$ 27,293,798
Accounts receivable	98,736	56,694
Prepaid expenses and other assets	789,285	369,259
Total current assets	68,381,068	27,719,751
Property and equipment, net	2,690,579	840,387
Other assets	374,004	336,708
Total Assets	71,445,651	28,896,846
Current liabilities:
Accounts payable	1,040,868	747,799
Accrued expenses	1,934,411	1,841,808
Current portion of long-term debt	5,225,818	1,898,548
Total current liabilities	8,201,097	4,488,155
Long-term debt, less current portion	11,246,188	13,053,117
Derivative financial instruments	3,297,077	3,006,021
Total liabilities	$ 22,744,362	$ 20,547,293
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.001 par value, 20,000,000 shares authorized, 60,600 shares outstanding at each of December 31, 2015 and 2014, designated as Series A Convertible Preferred Stock with liquidation preference of $606,000 at each of December 31, 2015 and 2014	$ 60	$ 60
Common stock, $0.0001 par value, 150,000,000 shares authorized at December 31, 2015 and 2014; 29,737,601 and 18,915,793 issued and outstanding at December 31, 2015 and 2014, respectively	2,974	1,891
Additional paid-in capital	157,585,498	89,739,511
Accumulated deficit	(108,887,243)	(81,391,909)
Total stockholders’ equity	48,701,289	8,349,553
Total Liabilities and Stockholders’ Equity	$ 71,445,651	$ 28,896,846

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares outstanding	60,600	60,600
Series A Convertible Preferred Stock, liquidation preference (in dollars)	$ 606,000	$ 606,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	29,737,601	18,915,793
Common stock, shares outstanding	29,737,601	18,915,793

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Royalty income	$ 274,648	$ 270,178	$ 259,246
License fees	0	10,000	0
Diagnostic service revenue	13,789	0	0
Other revenue	24,375	0	0
Total revenues	312,812	280,178	259,246
Costs and expenses:
Cost of revenue	629,191	15,441
Research and development	10,593,869	6,664,906	3,947,589
Selling and marketing	6,443,578	2,734,903	1,530,160
General and administrative	7,919,826	5,810,087	5,472,038
Total operating expenses	25,586,464	15,225,337	10,949,787
Loss from operations	(25,273,652)	(14,945,159)	(10,690,541)
Interest income	57,261	12,239	3,663
Interest expense	(1,525,482)	(843,259)	(17,005)
Other (income) expense, net	(2,800)	24,845	(22,941)
Gain (loss) from change in fair value of derivative instruments—warrants	(726,421)	1,425,850	(1,084,114)
Net loss and comprehensive loss	(27,471,094)	(14,325,484)	(11,810,938)
Preferred stock dividend	(24,240)	(23,015)	(29,840)
Net loss and comprehensive loss attributable to common stockholders	$ (27,495,334)	$ (14,348,499)	$ (11,840,778)
Net loss per common share - basic (in dollars per share)	$ (1.05)	$ (0.76)	$ (0.70)
Net loss per common share - diluted (in dollars per share)	$ (1.21)	$ (0.88)	$ (0.70)
Weighted-average shares outstanding - basic (in shares)	26,201,713	18,904,280	16,978,212
Weighted-average shares outstanding - diluted (in shares)	26,452,165	19,071,112	16,978,212

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Total	Series A Convertible Preferred Stock	Preferred Stock	Preferred StockSeries A Convertible Preferred Stock	Common Stock	Common StockMultiGen Diagnostics, Inc	Common StockShareholder of the Company	Additional Paid-In Capital	Additional Paid-In CapitalMultiGen Diagnostics, Inc	Additional Paid-In CapitalShareholder of the Company	Deficit Accumulated	Public Offering And Private Placement	Public Offering And Private PlacementCommon Stock
Balance (in shares) at Dec. 31, 2012			95,600		15,478,177
Balance at Dec. 31, 2012	$ 2,169,028		$ 96		$ 1,547			$ 57,370,017			$ (55,202,632)
Increase (Decrease) in Stockholders' Equity
Sale of common stock, net of expenses (in shares)					2,631,332
Sale of common stock, net of expenses	18,829,644							18,829,381				$ 18,829,644	$ 263
Issuance of warrants in connection with services	198,791							198,791
Stock-based compensation	1,979,364							1,979,364
Derivative liability — Warrants reclassified to additional paid-in capital	5,417,871							5,417,871
Conversion of Series A preferred stock and issuance of common stock (in shares)		(35,000)		(35,000)
Conversion of preferred stock and issuance of common stock				$ 36
Number of shares issued upon conversion of preferred stock into common stock		36,458			36,458		36,458
Conversion of Series A preferred stock and issuance of common stock					$ 4					$ 32
Issuance of common stock upon net exercise of warrant (in shares)					7,284	7,284
Issuance of common stock upon net exercise of warrant						$ 1			$ (1)
Issuance of common stock upon exercise of warrant (in shares)					715,743
Issuance of common stock upon exercise of warrants	3,599,831				$ 72			3,599,759
Issuance of common stock upon net exercise of stock option (in shares)					22,955
Issuance of common stock upon net exercise of stock options					$ 2			(2)
Issuance of common stock upon exercise of stock options (in shares)					10,833
Issuance of common stock upon exercise of stock options	38,249				$ 1			38,248
Preferred stock dividend	(29,840)										(29,840)
Net loss	(11,810,938)										(11,810,938)
Balance (in shares) at Dec. 31, 2013			60,600		18,902,782
Balance at Dec. 31, 2013	20,392,000		$ 60		$ 1,890			87,433,460			(67,043,410)
Increase (Decrease) in Stockholders' Equity
Issuance of warrant in connection with debt agreement	235,857							235,857
Stock-based compensation	2,070,195							2,070,195
Issuance of common stock upon net exercise of warrant (in shares)					13,011
Issuance of common stock upon net exercise of warrant					$ 1			(1)
Preferred stock dividend	(23,015)										(23,015)
Net loss	(14,325,484)										(14,325,484)
Balance (in shares) at Dec. 31, 2014			60,600		18,915,793
Balance at Dec. 31, 2014	8,349,553		$ 60		$ 1,891			89,739,511			(81,391,909)
Increase (Decrease) in Stockholders' Equity
Sale of common stock, net of expenses (in shares)					9,996,531
Sale of common stock, net of expenses	61,215,399				$ 1,000			61,214,399
Stock-based compensation	3,946,027							3,946,027
Derivative liability — Warrants reclassified to additional paid-in capital	435,365							435,365
Issuance of common stock upon net exercise of warrant (in shares)					277,136
Issuance of common stock upon net exercise of warrant					$ 28			(28)
Issuance of common stock upon exercise of warrant (in shares)					282,975
Issuance of common stock upon exercise of warrants	1,389,427				$ 28			1,389,399
Issuance of common stock upon exercise of stock options (in shares)					265,166
Issuance of common stock upon exercise of stock options	860,852				$ 27			860,825
Preferred stock dividend	(24,240)										(24,240)
Net loss	(27,471,094)										(27,471,094)
Balance (in shares) at Dec. 31, 2015			60,600		29,737,601
Balance at Dec. 31, 2015	$ 48,701,289		$ 60		$ 2,974			$ 157,585,498			$ (108,887,243)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating activities
Net loss	$ (27,471,094)	$ (14,325,484)	$ (11,810,938)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss (gain) on disposal of fixed assets	4,562	(24,845)	22,941
Depreciation and amortization	378,711	234,813	130,520
Stock-based compensation expense	3,946,027	2,070,194	1,979,364
Amortization of debt costs	346,157	248,799
Accretion of discount on debt	88,123	57,117
Change in fair value of financial instruments	726,421	(1,425,850)	1,084,114
Stock and warrant issued in connection with consulting services	0	0	198,791
Changes in operating assets and liabilities:
Decrease (increase) in other assets	(37,296)	(258)	25,631
Decrease (increase) in accounts receivable	(42,042)	22,300	89,387
Increase in prepaid expenses	(420,026)	(216,470)	(92,748)
Increase in accounts payable and accrued expenses	361,432	632,299	1,055,690
Net cash used in operating activities	(22,119,025)	(12,727,385)	(7,317,248)
Investing activities:
Capital expenditures	(2,241,066)	(363,290)	(649,784)
Proceeds from disposals of capital equipment	7,600	63,500	500
Net cash used in investing activities	(2,233,466)	(299,790)	(649,284)
Financing activities
Proceeds from sale of common stock, net of expenses	61,215,399	0	18,829,644
Proceeds from exercise of warrants	1,389,427	0	3,599,831
Proceeds from exercise of options	860,852	0	38,249
Borrowings under equipment line of credit	1,086,062	0	515,964
Repayments under equipment line of credit	0	(515,964)	0
Borrowings under debt agreement	0	15,000,000	0
Net cash provided by financing activities	64,551,740	14,484,036	22,983,688
Net change in cash and cash equivalents	40,199,249	1,456,861	15,017,156
Cash and cash equivalents—Beginning of period	27,293,798	25,836,937	10,819,781
Cash and cash equivalents—End of period	67,493,047	27,293,798	25,836,937
Supplementary disclosure of cash flow activity:
Cash paid for taxes	16,934	2,400	7,650
Cash paid for interest	1,061,993	425,256	9,459
Supplemental disclosure of non-cash investing and financing activities:
Warrants issued in connection with Loan and Security Agreement	0	235,857	0
Reclassification of derivative financial instruments to additional paid-in capital	435,365	0	(5,417,871)
Preferred stock dividends accrued	$ 24,240	$ 23,015	$ 29,840

Business Overview and Liquidity

Business Overview and Liquidity	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview and Liquidity	Business Overview and Liquidity Trovagene, Inc. (“Trovagene” or the “Company”) is a molecular diagnostic company that focuses on the development and commercialization of a proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. Trovagene’s primary internal focus is to leverage its novel urine-based molecular diagnostic platform to facilitate improvements in the field of oncology, while the Company’s external focus includes entering into collaborations to develop the Company’s technology in areas such as infectious disease, transplant medicine and prenatal genetics. The Company’s goal is to improve treatment outcomes for cancer patients using its proprietary technology to detect and quantitatively monitor cell-free DNA in urine. To date, Trovagene’s efforts have been principally devoted to research and development, securing and protecting patents and raising capital. Through December 31, 2015 , the Company sustained cumulative net losses attributed to common stockholders of $108,887,243 . The Company’s losses have resulted primarily from expenditures incurred in connection with research and development activities, stock-based compensation expense, patent filing and maintenance expenses, outside accounting and legal services and regulatory, scientific and financial consulting fees, amortization and liquidated damages. To date, the Company has generated only limited revenue from operations and expects to incur additional losses to perform further research and development activities as well as expenses related to the commercialization of the diagnostic tests the Company had commercially available as of December 31, 2015 . Liquidity The Company will need to continue to raise funds until it is able to generate revenues from operations sufficient to fund its development and commercial operations. Cash used in operating activities was $22,119,025 , $12,727,385 , and $7,317,248 for the years ended December 31, 2015 , 2014 , and 2013 , respectively. During the years ended December 31, 2015 , 2014 , and 2013 , the Company incurred net loss and comprehensive loss attributable to common stockholders of $27,495,334 , $14,348,499 , and $11,840,778 , respectively. The Company believes that it currently has adequate capital to continue operations for the next twelve months. However, to carry the Company forward beyond the next twelve months, and until it can generate adequate cash flow from operations, additional cash resources will be necessary. To date, Trovagene’s sources of cash have been primarily limited to the sale of debt and equity securities and debt financing. Net cash provided by financing activities for the years ended December 31, 2015 , 2014 , and 2013 was $64,551,740 , $14,484,036 and $22,983,688 , respectively. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact the Company’s ability to conduct its business. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more of its product candidates. The Company may also be required to: • Seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; and • Relinquish licenses or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize itself.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies The accompanying consolidated financial statements of Trovagene, which include its wholly owned subsidiary Trovagene Srl, a subsidiary formed in Italy, have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist of operating and money market accounts as of December 31, 2015 and 2014 on deposit with U.S. commercial banks. Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposit accounts that are not insured by the Federal Deposit Insurance Corporation in federally insured financial institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held. Revenues Revenue is recognized when persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured. Milestone, Royalty and License Revenues The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners. These agreements may involve multiple elements such as license fees, royalties and milestone payments. Revenue is recognized when the criteria described above have been met as well as the following: • Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured. • Minimum royalties are recognized as earned, and royalties in excess of minimum amounts are recognized upon receipt of payment when collection is assured. • Milestone payments are recognized when both the milestone is achieved and the related payment is received. Diagnostic Service Revenues Revenue for clinical laboratory tests may come from several sources, including commercial third-party payors, such as insurance companies and health maintenance organizations, government payors, such as Medicare and Medicaid in the United States, patient self-pay and, in some cases, from hospitals or referring laboratories who, in turn, might bill third-party payors for testing. The Company is recognizing diagnostic service revenue on the cash collection basis until such time as it is able to properly estimate collections on third party reimbursements. Allowance for Doubtful Accounts The Company reviews the collectability of accounts receivable based on an assessment of historic experience, current economic conditions, and other collection indicators. At each of December 31, 2015 , 2014 and 2013 , the Company had not recorded an allowance for doubtful accounts. When accounts are determined to be uncollectible, they are written off against the reserve balance and the reserve is reassessed. When payments are received on reserved accounts, they are applied to the individual’s account and the reserve is reassessed. Derivative Financial Instruments—Warrants The Company has issued common stock warrants in connection with the execution of certain equity financings. Such warrants are classified as derivative liabilities under the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815, Derivatives and Hedging (“ASC 815”) and are recorded at their fair market value as of each reporting period. Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1) indexed to its own stock and (2) classified in stockholders’ equity. Changes in fair value of derivative liabilities are recorded in the consolidated statement of operations under the caption “Change in fair value of derivative instruments.” The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding the volatility of Trovagene’s common stock price, the remaining life of the warrant, and the risk-free interest rates at each period end. The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value and accordingly classifies such warrants in Level 3 per FASB ASC Topic 820, Fair Value Measurements (“ASC 820”). At December 31, 2015 and 2014 , the fair value of these warrants was $3,297,077 and $3,006,021 , respectively, and was included in the derivative financial instruments liability on the balance sheet. Stock-Based Compensation FASB ASC Topic 718 “ Compensation—Stock Compensation ” (“ASC 718”) requires companies to measure the cost of employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant. The expense is recognized over the period during which an employee is required to provide services in exchange for the award. ASC 718 did not change the way Trovagene accounts for non-employee stock-based compensation. Trovagene continues to account for shares of common stock, stock options and warrants issued to non-employees based on the fair value of the stock, stock option or warrant, if that value is more reliably measurable than the fair value of the consideration or services received. The Company accounts for stock options issued and vesting to non-employees in accordance with FASB ASC Topic 505-50 “ Equity -Based Payment to Non-Employees ” , and, accordingly, the value of the stock compensation to non-employees is based upon the measurement date as determined at either (1) the date at which a performance commitment is reached, or (2) the date at which the necessary performance to earn the equity instruments is complete. Therefore, the fair value of these options is being “marked to market” quarterly until the measurement date is determined. Fair Value of Financial Instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, debt and derivative liabilities. The Company has adopted ASC 820 for financial assets and liabilities that are required to be measured at fair value and non-financial assets and liabilities that are not required to be measured at fair value on a recurring basis. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short term nature as they reflect current market interest rates. Debt is stated at its respective historical carrying amounts, which approximate fair value as they reflect current market interest rates. In accordance with FASB ASC Subtopic 820-10, the Company measures certain assets and liabilities at fair value on a recurring basis using the three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The three tiers include: • Level 1 — Quoted prices for identical instruments in active markets. • Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable. • Level 3 — Instruments where significant value drivers are unobservable to third parties. Property, Equipment and Depreciation and Amortization Expenditures for additions, renewals and improvements are capitalized at cost. Depreciation and amortization is generally computed on a straight-line method based on the estimated useful lives of the related assets. Amortization of leasehold improvements is computed based on the shorter of the life of the asset or the term of the lease. The estimated useful lives of the major classes of depreciable assets are three to five years for laboratory equipment and furniture and fixtures. Expenditures for repairs and maintenance are charged to operations as incurred. Impairment of Indefinite and Long-Lived Assets The Company reviews its long-lived and indefinite assets to determine if any event has occurred that may indicate its intangible assets with indefinite lives and other long-lived assets are potentially impaired. If indicators of impairment exist, the Company performs an impairment test to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, the Company estimates the fair value of the assets and records an impairment loss if the carrying value of the assets exceeds the fair value. Factors that would indicate potential impairment include a significant decline in the Company’s stock price and market capitalization compared to its net book value, significant changes in the ability of a particular asset to generate positive cash flows, and significant changes in the Company’s strategic business objectives and utilization of a particular asset. The Company noted no indications of impairment for the years ended December 31, 2015 , 2014 , and 2013 . Income Taxes Income taxes are determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes result from differences between the financial statement and tax bases of Trovagene’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment. Contingencies In the normal course of business, Trovagene is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations, stockholder lawsuits, product and environmental liability, and tax matters. In accordance with FASB ASC Topic 450, Accounting for Contingencies , Trovagene records such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Trovagene, in accordance with this guidance, does not recognize gain contingencies until realized. Cost of Revenue Cost of revenue represents the cost of materials, personnel costs, costs associated with processing specimens including pathological review, quality control analyses, and delivery charges necessary to render an individualized test result. Costs associated with performing tests are recorded as the tests are processed. Research and Development Research and development expenses, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, purchased in-process research and development and regulatory and scientific consulting fees, as well as contract research and insurance, are accounted for in accordance with FASB ASC Topic 730-10-55-2, Research and Development. Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any. While certain of the Company’s research and development costs may have future benefits, the Company’s policy of expensing all research and development expenditures is predicated on the fact that Trovagene has no history of successful commercialization of molecular diagnostic products to base any estimate of the number of future periods that would be benefited. FASB ASC Topic 730, Research and Development requires that non-refundable advance payments for goods or services that will be used or rendered for future research and development activities be deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts are recognized as an expense. There were no non-refundable advance payments as of December 31, 2015 , 2014 and 2013 . Net Loss Per Share Basic and diluted net loss per share is presented in conformity with FASB ASC Topic 260, Earnings per Share , for all periods presented. In accordance with this guidance, basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share. Shares used in calculating diluted net loss per common share exclude as anti-dilutive the following share equivalents: December 31, 2015 2014 2013 Options to purchase Common Stock 6,948,630 4,913,472 4,287,545 Warrants to purchase Common stock 4,565,947 5,251,660 6,233,483 Series A Convertible Preferred Stock 63,125 63,125 63,125 11,577,702 10,228,257 10,584,153 The following table summarizes the Company’s diluted net loss per share: December 31, 2015 2014 2013 Numerator: Net loss attributable to common stockholders $ (27,495,334 ) $ (14,348,499 ) $ (11,840,778 ) Adjustment for change in fair value of derivative instruments - warrants (4,396,061 ) (2,422,337 ) — Net loss used for diluted loss per share $ (31,891,395 ) $ (16,770,836 ) $ (11,840,778 ) Denominator: Weighted-average shares used to compute basic net loss per share 26,201,713 18,904,280 16,978,212 Adjustments to reflect assumed exercise of warrants 250,452 166,832 — Weighted-average shares used to compute diluted net loss per share 26,452,165 19,071,112 16,978,212 Net loss per share diluted $ (1.21 ) $ (0.88 ) $ (0.70 ) Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases . The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact the adoption of the new standard will have on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, P resentation of Financial Statements — Going Concern , which impacts the accounting guidance related to the evaluation of an entity’s ability to continue as a going concern. The amendment establishes management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern in connection with preparing financial statements for each annual and interim reporting period. The amendment also gives guidance to determine whether to disclose information about relevant conditions and events when there is substantial doubt about an entity’s ability to continue as a going concern. The amended guidance is effective prospectively for fiscal years beginning after December 15, 2016. The new guidance is not expected to have a material impact on the Company’s financial position, results of operations or cash flows. In May 2014, the FASB issued ASU 2014-9, Revenue from Contracts with Customers (“ASU 2014-9”). ASU 2014-9 provides companies with a single model for accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the model is to recognize revenue when control of the goods or services transfers to the customer, as opposed to recognizing revenue when the risks and rewards transfer to the customer under the existing revenue guidance. The guidance permits companies to either apply the requirements retrospectively to all prior periods presented, or apply the requirements in the year of adoption, through a cumulative adjustment. In August 2015, the FASB issued ASU 2015-14, Deferral of the Effective Date , which defers the required adoption date of ASU 2014-09 by one year. As a result of the deferred effective date, ASU 2014-09 will be effective for the Company in its first quarter of fiscal year 2018. Early adoption is permitted but not before the original effective date of the first quarter of fiscal year 2017. The Company is in the process of evaluating the transition method that will be elected and the impact of adoption of ASU 2014-09 on its consolidated financial statements.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Fixed assets consist of laboratory, testing and computer equipment and fixtures stated at cost. Depreciation and amortization expense for the years ended December 31, 2015 , 2014 , and 2013 was $378,711 , $234,813 , and $130,520 , respectively. Property and equipment consisted of the following: As of December 31, 2015 2014 Furniture and office equipment $ 1,483,227 $ 365,955 Leasehold Improvements 39,401 39,401 Laboratory equipment 2,022,733 968,901 3,545,361 1,374,257 Less—accumulated depreciation and amortization (854,782 ) (533,870 ) Property and equipment, net $ 2,690,579 $ 840,387

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity (Deficit)	Stockholders’ Equity (Deficit) Common Stock On January 25, 2013, the Company filed a Registration Statement on Form S-3 (the “Registration Statement”) to offer and sell in one or more offerings, any combination of common stock, preferred stock, warrants, or units having an aggregate initial offering price of up to $150,000,000 . If issued, the preferred stock, warrants and units would be convertible, exercisable or exchangeable for common stock, preferred stock or other Trovagene securities. The Registration Statement was declared effective on February 4, 2013. In addition, in connection with the Registration Statement, the Company entered into an agreement with Cantor Fitzgerald & Co. (“Agent”) on January 25, 2013 to issue and sell up to $30,000,000 of shares of common stock. As payment for its services, the Agent is entitled to a 3% commission on gross proceeds on sales of the Company’s securities. The Company received gross proceeds of approximately $4.2 million from the sale of 488,476 shares of its common stock during the year ended December 31, 2013 under the agreement with the Agent. In addition, the Company received gross proceeds of approximately $15.0 million from the sale of 2,142,857 shares of its common stock through a registered direct offering that occurred in July 2013. During the year ended December 31, 2013, the Company issued a total of 3,424,605 shares of common stock. The Company sold 2,631,332 shares of common stock for net proceeds of $18,829,644 . In addition, 36,458 shares were issued upon conversion of Series A Preferred Stock, 715,743 shares were issued upon exercise of 715,743 warrants for a weighted-average price of $5.02 and 7,284 shares were issued upon net exercise of 12,745 warrants at an exercise price of $3.00 . The remaining 33,788 shares include 22,955 shares that were issued upon net exercise of an option to purchase 41,667 shares of common stock at an exercise price of $4.50 and the exercise of an option to purchase 10,833 shares of common stock at a weighted-average exercise price of $3.53 . During the year ended December 31, 2014, the Company issued a total of 13,011 shares of common stock upon the net exercise of warrants at a weighted-average exercise price of $3.00 . During the year ended December 31, 2015 , the Company issued a total of 10,821,808 shares of common stock. The Company received gross proceeds of approximately $63.2 million from the sale of 9,711,110 shares of its common stock through underwritten public offerings in February 2015 and July 2015. The Company also received gross proceeds of approximately $2.8 million from the sale of 285,421 shares of its common stock at a weighted-average price of $9.66 under the agreement with the Agent. In addition, 265,166 shares were issued upon exercise of options for a weighted-average price of $3.25 , 282,975 shares were issued upon exercise of warrants for a weighted-average price of $4.91 , and 277,136 shares were issued upon net exercise of 449,403 warrants at a weighted-average exercise price of $3.05 . Warrants A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications, is presented below: Number of Warrants Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Term Balance outstanding, December 31, 2012 6,985,070 $ 3.96 5.4 Granted 50,000 $ 8.00 Exercised (728,488 ) $ 4.99 Expired (73,099 ) $ 4.50 Balance outstanding, December 31, 2013 6,233,483 $ 3.87 4.5 Granted 85,470 $ 3.51 Exercised (36,666 ) $ 3.00 Expired (16,667 ) $ 10.80 Balance outstanding, December 31, 2014 6,265,620 $ 3.85 3.6 Exercised (732,378 ) $ 3.77 Balance outstanding, December 31, 2015 5,533,242 $ 3.86 2.5 The Company issued a warrant to purchase 50,000 shares of common stock at an exercise price of $8.00 per share during the year ended December 31, 2013. The warrant was issued in connection with an agreement to provide services related to investor and public relations materials and expires three years from date of grant. The estimated fair value of the warrant was determined on the date of grant using the Black-Scholes option valuation model using the following assumptions: a risk-free interest rate of 0.42% , dividend yield of 0% , expected volatility of 97% and expected term of three years. The resulting fair value of $198,791 was recorded as stock-based compensation expense. The Company issued warrants to purchase 85,470 shares of common stock at an exercise price of $3.51 per share during the year ended December 31, 2014. The warrants were issued in connection with a $15.0 million debt agreement. The estimated fair value of the warrants was determined on the date of grant using the Black-Scholes option valuation model using the following assumptions: a risk-free interest rate of 2.53% , dividend yield of 0% , expected volatility of 73.8% and expected term of ten years . The resulting fair value of $235,857 was recorded as a debt discount and was amortized to interest expense over the term of the loan using the effective interest method. Series A Convertible Preferred Stock The material terms of the Series A Convertible Preferred Stock consist of: 1) Dividends. Holders of the Company’s Series A Convertible Preferred Stock are entitled to receive cumulative dividends at the rate per share of 4% per annum, payable quarterly on March 31, June 30, September 30 and December 31, beginning with September 30, 2005. Dividends are payable, at the Company’s sole election, in cash or shares of common stock. As of December 31, 2015 , 2014 , and 2013 , the Company had $268,295 , $244,055 , and $221,040 , respectively in accrued cumulative unpaid preferred stock dividends, included in Accrued Expenses in the Company’s consolidated balance sheets, and $24,240 , $23,015 , and $29,840 of accrued dividends was recorded during the years ended December 31, 2015 , 2014 , and 2013 , respectively. 2) Voting Rights. Shares of the Series A Convertible Preferred Stock have no voting rights. However, so long as any shares of Series A Convertible Preferred Stock are outstanding, the Company may not, without the affirmative vote of the holders of the shares of Series A Convertible Preferred Stock then outstanding, (a) adversely change the powers, preferences or rights given to the Series A Convertible Preferred Stock, (b) authorize or create any class of stock senior or equal to the Series A Convertible Preferred Stock, (c) amend its certificate of incorporation or other charter documents, so as to affect adversely any rights of the holders of Series A Convertible Preferred Stock or (d) increase the authorized number of shares of Series A Convertible Preferred Stock. 3) Liquidation. Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series A Convertible Preferred Stock are entitled to receive an amount equal to the Stated Value per share, which is currently $10 per share plus any accrued and unpaid dividends. 4) Conversion Rights. Each share of Series A Convertible Preferred Stock is convertible at the option of the holder into that number of shares of common stock determined by dividing the Stated Value, currently $10 per share, by the conversion price, originally $2.15 per share. 5) Subsequent Equity Sales. The conversion price is subject to adjustment for dilutive issuances for a period of 12 months beginning upon registration of the common stock underlying the Series A Convertible Preferred Stock. The relevant registration statement became effective on March 17, 2006 and during the following twelve month period the conversion price was adjusted to $9.60 per share. 6) Automatic Conversion. If the price of the Company’s common stock equals $25.80 per share for 20 consecutive trading days, and an average of 8,333 shares of common stock per day are traded during the 20 trading days, the Company will have the right to deliver a notice to the holders of the Series A Convertible Preferred Stock, requesting the holders to convert any portion of the shares of Series A Convertible Preferred Stock into shares of common stock at the applicable conversion price. As of the date of these financial statements, such conditions have not been met. During the year ended December 31, 2013, 35,000 shares of Series A Convertible Preferred Stock were converted into 36,458 shares of common stock, on a net converted basis. As of each of December 31, 2015 , 2014 , and 2013 , there were 60,600 shares of Series A Convertible Preferred Stock outstanding.

Stock Option Plan

Stock Option Plan	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Option Plan	Stock Option Plan In June 2004, the Company adopted the Trovagene Stock Option Plan, as amended (the “2004 Plan”), under which up to 6,000,000 shares common stock were reserved for issuance to directors and eligible employees, including executive officers and consultants. Generally, vesting for options granted under the Plan was from three to four years , and options expired after a 10 -year period. Options were granted at an exercise price not less than the fair market value at the date of grant. As of December 31, 2014, the 2004 Plan was expired. As of December 31, 2013, there were 1,788,921 shares available for issuance under the 2004 Plan. During 2013, the Company issued 260,000 options over the authorized number of options in the 2004 Plan. As per FASB ASC Topic 815-40, the options were accounted for as liabilities and recorded at fair value with the changes in fair value being recorded in the Company’s statement of operations. Stockholder approval was obtained on July 18, 2013 to increase the number of authorized shares in the 2004 Plan from 3,666,667 to 6,000,000 . Accordingly, the options were remeasured as of the date of stockholder approval with the change recorded in stock based compensation expense and the $23,024 liability was reclassified to additional paid-in capital. In July 2013, an option to purchase 90,000 shares of common stock was granted to a member of the Board for services provided outside of routine Board activities. This option was vested in full upon grant. The fair value of this option was approximately $500,000 and is included in general and administrative expenses. The Trovagene, Inc. 2014 Equity Incentive Plan (the “2014 EIP’), authorizing up to 2,500,000 shares of common stock for issuance under the 2014 EIP, was approved by the Board in June 2014 and approved by the stockholders of the Company at the September 17, 2014 Annual Meeting of Stockholders. An additional 2,500,000 shares of common stock was authorized for issuance by the Board in March 2015 and was approved by the stockholders at the June 10, 2015 Annual Meeting of Stockholders. As of December 31, 2015 , there were 1,361,832 shares available for issuance under the 2014 EIP. Stock-based compensation has been recognized in operating results as follows: Years ended December 31, 2015 2014 2013 In cost of revenue $ 39,676 $ — $ — In research and development expenses 1,499,009 796,008 549,465 In selling and marketing expense 768,146 145,239 70,626 In general and administrative expenses 1,639,196 1,128,947 1,359,273 Total stock-based compensation $ 3,946,027 $ 2,070,194 $ 1,979,364 The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the years indicated below: Years ended December 31, 2015 2014 2013 Risk-free interest rate 1.35% - 2.15% 1.42% - 2.1% 0.74% - 1.5% Dividend yield 0% 0% 0% Expected volatility (range) 73% - 77% 81% - 86% 82% - 100% Expected volatility (weighted-average) 75% 85% 91% Expected term (in years) 6.0 years 5.8 years 5.0 years Risk-free interest rate — Based on the daily yield curve rates for U.S. Treasury obligations with maturities that correspond to the expected term of the Company’s stock options. Dividend yield — Trovagene has not paid any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable future. Expected volatility — Based on the historical volatility of a group of peer companies with attributes similar to Trovagene. Expected term — The expected option term represents the period that stock-based awards are expected to be outstanding based on the simplified method provided in Staff Accounting Bulletin (“SAB”) No. 107, Share-Based Payment (“SAB No. 107”), which averages an award’s weighted-average vesting period and expected term for “plain vanilla” share options. Under SAB No. 107, options are considered to be “plain vanilla” if they have the following basic characteristics: (1) are granted “at-the-money”; (2) exercisability is conditioned upon service through the vesting date; (3) termination of service prior to vesting results in forfeiture; (4) limited exercise period following termination of service; and (5) are non-transferable and non-hedgeable. Forfeitures — FASB ASC Topic 718 (“ASC 718”) requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company estimates forfeitures based on its historical experience. The weighted-average fair value per share of all options granted during the years ended December 31, 2015 , 2014 , and 2013 , estimated as of the grant date using the Black-Scholes option valuation model, was $4.60 , $3.16 and $4.54 per share, respectively. The unrecognized compensation cost related to non-vested stock options outstanding at December 31, 2015 and 2014 was $10,430,604 and $4,862,030 , respectively. The weighted-average remaining contractual term at December 31, 2015 and 2014 for options outstanding and vested options was 3.1 years and 3.0 years , respectively. The total intrinsic value of stock options exercised was $1,382,255 , $0 and $275,492 during the years ended December 31, 2015 , 2014 and 2013 , respectively. The total fair value of shares vested during the years ended December 31, 2015 , 2014 and 2013 was $2,634,688 , $1,960,256 and $1,633,071 , respectively. A summary of stock option activity and of changes in stock options outstanding is presented below: Number of Options Weighted-Average Exercise Price Per Share Intrinsic Value Weighted-Average Remaining Contractual Life Balance outstanding, December 31, 2012 3,711,303 $ 4.69 $ 8,301,484 6.3 years Granted 1,144,760 $ 6.33 Exercised (52,500 ) $ 4.30 Forfeited (516,018 ) $ 4.35 Balance outstanding, December 31, 2013 4,287,545 $ 5.18 $ 5,896,329 6.7 years Granted 1,410,038 $ 4.42 Forfeited (784,111 ) $ 7.08 Balance outstanding, December 31, 2014 4,913,472 $ 4.66 $ 2,808,083 7.6 years Granted 2,688,500 $ 7.02 Exercised (265,166 ) $ 3.25 Forfeited (388,176 ) $ 7.75 Balance outstanding, December 31, 2015 6,948,630 $ 5.45 $ 5,903,466 7.8 years Vested and exercisable, December 31, 2015 2,825,398 $ 4.38 $ 4,194,205 6.0 years ASC 718 requires that cash flows resulting from tax deductions in excess of the cumulative compensation cost recognized for options exercised (excess tax benefits) be classified as cash inflows from financing activities and cash outflows from operating activities. Due to Trovagene’s accumulated deficit position, no tax benefits have been recognized in the cash flow statement.

Derivative Financial Instrument

Derivative Financial Instruments - Warrants	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments - Warrants	Derivative Financial Instruments — Warrants Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”), Trovagene has determined that certain warrants issued in connection with its private placements must be recorded as derivative liabilities with a charge to additional paid-in capital as they were issued with other equity instruments. In accordance with ASC 815-40, the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant change in fair value is being recorded in the Company’s statement of operations. The Company estimates the fair value of these warrants using the Black-Scholes option pricing model. The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was: Year ended December 31 2015 2014 2013 Estimated fair value of Trovagene common stock $5.40 - $10.15 $3.00 - $6.74 $5.74 - $7.18 Expected warrant term 3.0-3.8 years 4.0 years 1 month to 5.8 years Risk-free interest rate 0.89%-1.31% 1.38% .03%-1.75% Expected volatility 73%-77% 86.4% 82%-100% Dividend yield —% —% —% Expected volatility is based on the volatility of a peer group of companies with attributes similar to Trovagene. The warrants have a transferability provision and based on guidance provided in SAB No. 107 for instruments issued with such a provision, Trovagene used the full contractual term as the expected term of the warrants. The risk-free interest rate is based on the U.S. Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date. The following table sets forth the components of changes in the Company’s derivative financial instruments liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. Date Description Number of Warrants Derivative Instrument Liability December 31, 2013 Balance of derivative financial instruments liability 1,013,961 $ 4,431,871 Change in fair value of warrants during the year recognized as a gain in the statement of operations — (1,425,850 ) December 31, 2014 Balance of derivative financial instruments liability 1,013,961 3,006,021 Exercised warrants (46,666 ) (435,365 ) Change in fair value of warrants during the year recognized as a loss in the statement of operations — 726,421 December 31, 2015 Balance of derivative financial instruments liability 967,295 $ 3,297,077 The weighted-average remaining contractual term of all of the Company’s warrants outstanding at December 31, 2015 and 2014 was approximately 2.5 and 3.6 years, respectively. At December 31, 2015 and 2014 , the total fair value of the above warrants accounted for as derivative financial instruments, valued using the Black-Scholes option pricing model, was $3,297,077 and $3,006,021 , respectively, and is classified as derivative financial instruments liability on the balance sheet.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December 31, 2015 and 2014 : Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities Significant Other Observable Inputs Significant Unobservable Inputs Total Assets: Money market fund (1) $ 65,016,222 $ — $ — $ 65,016,222 Total Assets $ 65,016,222 $ — $ — $ 65,016,222 Liabilities: Derivative liabilities related to warrants $ — $ — $ 3,297,077 $ 3,297,077 Total Liabilities $ — $ — $ 3,297,077 $ 3,297,077 Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities Significant Other Observable Inputs Significant Unobservable Inputs Total Assets: Money market fund (1) $ 27,123,587 $ — $ — $ 27,123,587 Total Assets $ 27,123,587 $ — $ — $ 27,123,587 Liabilities: Derivative liabilities related to warrants $ — $ — $ 3,006,021 $ 3,006,021 Total Liabilities $ — $ — $ 3,006,021 $ 3,006,021 (1) Included as a component of cash and cash equivalents on the accompanying consolidated balance sheet. The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the years ended December 31, 2015 and 2014 : Description Balance at Fair Value of Warrants Reclassified to Additional Paid-in Capital Unrealized (gains) or losses Balance at Derivative liabilities related to Warrants $ 3,006,021 $ (435,365 ) $ 726,421 $ 3,297,077 Description Balance at Unrealized (gains) or losses Balance at Derivative liabilities related to Warrants $ 4,431,871 $ (1,425,850 ) $ 3,006,021 The unrealized gains or losses on the derivative liabilities are recorded as a change in fair value of derivative liabilities in the Company’s statement of operations. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3.

Debt

Debt	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt	Debt Equipment Line of Credit In November 2015, the Company entered into a Loan and Security Agreement (“Equipment Line of Credit”) with Silicon Valley Bank that provided for cash borrowings for equipment (“Equipment Advances”) of up to $2.0 million , secured by the equipment financed. Under the terms of the agreement, interest is equal to 1.25% above the Prime Rate. Interest only payments are due on borrowings through November 30, 2016, with both interest and principal payments commencing in December 2016. Any equipment advances after November 30, 2016 are subject to principal and interest payments immediately over a 36 -month period following the advance. All unpaid principal and interest on each Equipment Advance will be due on November 1, 2019. The Company has an obligation to make a final payment equal to 7% of total amounts borrowed at the loan maturity date and the final payment is being accrued over the term of the loans using the effective-interest method. The Company is also subject to certain affirmative and negative covenants under the Equipment Line of Credit. As of December 31, 2015 , the Company was in compliance with all covenants. As of December 31, 2015 , $1,086,062 has been borrowed under the Equipment Line of Credit. As of December 31, 2015 , amounts due under the Equipment Line of Credit included $30,168 in current liabilities and $1,058,709 in long-term liabilities, which includes $2,815 of accrued financial payment. The Company recorded $5,702 in interest expense related to the Equipment Line of Credit during the year ended December 31, 2015 . Future maturities of long-term debt at December 31, 2015 are as follows: 2016 $ 30,168 2017 362,021 2018 362,021 2019 331,852 Total principal 1,086,062 Plus final fee premium accretion 2,815 Total long-term obligations $ 1,088,877 Loan and Security Agreement In June 2014, the Company entered into a $15,000,000 loan and security agreement (“Agreement”) with two banks pursuant to which the lenders provided the Company with a term loan, which was funded at closing. A portion of the proceeds were used to repay the existing outstanding amount under the Equipment Line of Credit entered into in June 2013. The repayment with the same lender was accounted for as a debt extinguishment under FASB ASC Topic 470-50, Debt . The interest rate on the new loan is 7.07% per annum. The Company made interest only payments on the outstanding amount of the loan on a monthly basis through July 2015, after which equal monthly payments of principal and interest were scheduled to become due until the loan maturity date of July 1, 2018. However, included in the Agreement is a provision to extend the interest only payments through January 1, 2016 upon the Company’s receipt of unrestricted net cash proceeds from the sale of equity securities of not less than $30 million by June 30, 2015. In June 2015, the Company entered into an amendment to the Agreement (“Amendment”), which reduced the amount of unrestricted net cash proceeds to not less than $21 million from the sale of equity securities to qualify for an interest-only extension. The Company met the conditions in the Amendment related to the interest-only extension and, as a result, the interest only payments that were to expire on August 1, 2015 were extended for six months to February 1, 2016, when both interest and principal payments will commence. The loan is secured by a security interest in all of the Company’s assets except intellectual property, which is subject to a negative pledge. In connection with the loan, each of the lenders received a warrant to purchase up to an aggregate of 85,470 shares of the Company’s common stock at an exercise price of $3.51 per share, which such warrants are exercisable for ten years from the date of issuance. The original value of the warrants, totaling $235,857 , was recorded as debt discount and additional paid-in capital as the warrants were equity classified. As of December 31, 2015 , a warrant to purchase 42,735 shares of common stock remains outstanding. At the Company’s option, it may prepay all of the outstanding principal balance, subject to certain pre-payment fees ranging from 1% to 3% of the prepayment amount. In the event of a final payment of the loans under the loan agreement, either in the event of repayment of the loan at maturity or upon any prepayment, the Company is obligated to pay the amortized portion of the final fee of $1,050,000 . The Company is also subject to certain affirmative and negative covenants under the Agreement, including limitations on its ability to: undergo certain change of control events; convey, sell, lease, license, transfer or otherwise dispose of any equipment financed by loans under the loan agreement; create, incur, assume, guarantee or be liable with respect to indebtedness, subject to certain exceptions; grant liens on any equipment financed under the loan agreement; make or permit any payment on specified subordinated debt; and pay dividends. In addition, under the Agreement, subject to certain exceptions, the Company is required to maintain with the lender its primary operating, other deposit and securities accounts. Furthermore, under the Amendment, the Company is required to be in compliance with healthcare laws and regulations and terms and conditions of healthcare permits. The Company was in compliance with all covenants under the Agreement, as amended, as of December 31, 2015 . As of December 31, 2015 , amounts due under the Agreement include $5,195,650 in current liabilities and $10,187,479 in long-term liabilities, which include $535,024 of accrued financial payment. The Company recorded $1,590,750 in interest expense related to the Agreement during the year ended December 31, 2015 . Closing costs are being accreted over the life of the loan to interest expense. Future maturities of long-term debt at December 31, 2015 are as follows: 2016 $ 5,195,650 2017 6,064,315 2018 3,740,035 Total principal 15,000,000 Less discount (151,895 ) Plus final fee premium accretion 535,024 Total long-term obligations $ 15,383,129

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes At December 31, 2015 , Trovagene had federal net operating loss carryforwards (NOLs) of approximately $72.6 million , which, if not used, expire beginning in 2020. Trovagene also has California NOLs of approximately $52.6 million that will begin to expire in 2021 and New Jersey NOLs of approximately $6.9 million that begin to expire on January 31, 2016. Trovagene also has research and development tax credits available for federal and California purposes of approximately $1.2 million and $0.5 million , respectively. The federal research and development tax credits will begin to expire on January 31, 2025. The California research and development tax credits are not set to expire. The utilization of these NOLs and research and development tax credits is subject to limitations based on past and future changes in ownership of Trovagene pursuant to Section 382 (“Section 382”) of the Internal Revenue Code of 1986, as amended (the “Code”). The Company has determined that ownership changes have occurred for purposes of Section 382 and, therefore, the ability of the Company to utilize its NOLs is limited. The provision for income taxes based on losses from continuing operations consists of the following at December 31 (in thousands): Years ended December 31, 2015 2014 2013 Deferred benefit Federal $ (9,602 ) $ (5,651 ) $ (3,806 ) State (1,742 ) (449 ) (593 ) Total deferred benefit (11,344 ) (6,100 ) (4,399 ) Valuation allowance 11,344 6,100 4,399 Total income tax provision $ — $ — $ — Significant components of the Company’s taxes and the rates as of December 31 are shown below (in thousands, except percentages): Years ended December 31, 2015 2014 Tax computed at the federal statutory rate $ (9,340 ) 34 % $ (4,871 ) 35 % State tax, net of federal tax benefit (1,559 ) 6 % (891 ) 6 % Permanent Items 258 (1 )% (320 ) 2 % Tax credits (997 ) 3 % — — % Valuation allowance increase 11,638 (42 )% 6,081 (43 )% Other — — % 1 — % Provision for income taxes $ — — % $ — — % Significant components of the Company’s deferred tax assets and liabilities from federal and state income taxes as of December 31 are shown below: Years ended December 31, 2015 2014 Deferred tax assets Tax loss carryforwards $ 27,962,000 $ 19,010,900 Research and development credits and other tax credits 1,698,300 698,000 Stock-based compensation 3,225,200 2,193,900 Other 782,000 420,800 Total deferred tax assets 33,667,500 22,323,600 Valuation allowance (33,667,500 ) (22,323,600 ) Net deferred tax asset $ — $ — Trovagene records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Due to the substantial doubt related to Trovagene’s ability to utilize its deferred tax assets, the Company recorded a valuation allowance against the deferred tax. FASB ASC Topic 740-10-30-7, Accounting for Income Taxes had no effect on Trovagene’s financial position, cash flows or results of operations upon adoption, as Trovagene does not have any unrecognized tax benefits. Trovagene’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense, and none have been incurred to date.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Research and Development and License Agreements The Company has entered into a variety of collaboration and specimen transfer agreements relating to its development efforts. Included in research and development expense, the Company has incurred and recorded approximately $1,362,000 , $712,000 , and $217,000 as of December 31, 2015 , 2014 and 2013 , respectively, relating to services provided by the collaborators in connection with these agreements. The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of human diagnostics. License fees are generally calculated as a percentage of product revenues, with rates that vary by agreement. To date, payments have not been material. Litigation Trovagene does not believe that the Company has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. The Company is not currently a party to any material legal proceedings. Employment and Consulting Agreements The Company has longer-term contractual commitments with various consultants and employees, including the Company’s CEO and CFO. The executive agreements with the CEO, CFO and CCO provide for severance payments. The executive agreement with the CEO also provides for a bonus payment in cash or stock upon the earlier of meeting certain trading volumes and market price of Trovagene’s common stock for a minimum period of ninety days or in the event of a change in control where the Company’s per share enterprise value equal or exceeds $7.50 . If the market price and volume target is realized, the bonus is approximately $3.5 million . If a change of control occurs at the targeted enterprise values, the bonus is equal to 4% of the enterprise value. The executive agreements with the CEO and CFO were replaced by the employment agreements that became effective in January 2016. See Note 14. Subsequent Events. Lease Agreements The Company leases laboratory and office spaces under various non-cancelable lease agreements. The Company is headquartered in San Diego, California and leases facilities in San Diego and Italy. The Company currently leases its facilities in San Diego under an operating lease that expires in 2017. On June 11, 2015, the Company entered into an amendment to the lease agreement which expands the square footage leased by the Company to approximately 22,600 square feet at a monthly rental rate of approximately $60,000 . The amended lease expires on December 31, 2021. The amended monthly rental rate will be effective when the Company commences business operations in the expanded premises, expected to occur in the second quarter of 2016. In November 2015, the Company entered into a lease agreement, under the terms of which the Company will lease certain office building in Torino, Italy, consisting of approximately 2,300 square feet at a monthly rental rate of approximately $3,100 . The lease is for a period of three years with an effective date of January 1, 2016. Rent expense for the years ended December 31, 2015 , 2014 , and 2013 was approximately $471,000 , $315,000 and $294,000 , respectively. The Company is also a party to various operating lease agreements for office equipment. Total annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows: 2016 $ 683,871 2017 792,221 2018 811,797 2019 796,716 2020 817,989 Thereafter 842,529 Total $ 4,745,123

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plan	Employee Benefit Plan The Company has a retirement savings plan under Section 401(k) of the Code covering its employees. The plan allows employees to defer, up to the maximum allowed, a percentage of their income on a pre-tax basis through contributions to the plans, plus any employee age 50 and over can participate in the caught-up dollars as allowed by Internal Revenue Service codes. The Company also has a Roth investment plan that is taken after taxes. The Company does not currently make matching contributions.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions In January 2015, the Company entered into a one year consulting agreement with Thomas H. Adams, Ph.D., the Chairman of the Board, pursuant to which Dr. Adams provides consulting services to the Company in connection with applying the Company’s technology in the field of infectious disease with the first application to be detection of John Cunningham virus mutants in the presence of wild type in human urine as a prognostic indicator of the development of progressive multifocal leukoencephalopathy disease. Under the agreement, the Company committed to pay $9,500 per month for the services performed by Dr. Adams. During the year ended December 31, 2015 , the Company incurred and recorded $114,000 of consulting fees related to the agreement. In September 2015, the Company entered into a research agreement with the University of Torino (“University”) to collaborate on a program of research to develop, optimize and test molecular profiling tools for plasma and urine ctDNA in cancer. Dr. Alberto Bardelli, the Principal Investigator of the University who oversees this research program, is also a member of the Scientific Advisory Board of the Company. Under the agreement, the Company committed to pay up to $529,000 for the services performed by the University. In addition, the Company may pay royalties to the University on revenue generated by the Company from the commercialization of any tools developed during the collaboration. During the year ended December 31, 2015 , the Company incurred and recorded approximately $188,000 of research and development expenses related to the agreement. No royalty expense has been incurred as of December 31, 2015 .

Selected Quarterly Financial Da

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Data [Abstract]
Selected Quarterly Financial Data (Unaudited)	Selected Quarterly Financial Data (Unaudited) The following is a summary of the quarterly results of operations of the Company for years ended December 31, 2015 and 2014 : Quarter Ended(1) March 31 June 30 September 30 December 31 (dollars in thousands, except per share data) 2015 Revenues $ 127 $ 49 $ 58 $ 79 Operating expenses $ 4,975 $ 6,682 $ 6,467 $ 7,463 Net loss and comprehensive loss attributable to common stockholders $ (7,180 ) $ (10,186 ) $ (2,742 ) $ (7,387 ) Net loss per common share - basic $ (0.33 ) $ (0.41 ) $ (0.10 ) $ (0.25 ) Net loss per common share - diluted $ (0.33 ) $ (0.41 ) $ (0.23 ) $ (0.26 ) Shares used in the calculation of net loss attributable to common stockholders - basic 21,817,710 24,592,883 28,560,211 29,723,254 Shares used in the calculation of net loss attributable to common stockholders - diluted 21,817,710 24,592,883 29,128,235 30,157,038 2014 Revenues $ 111 $ 56 $ 57 $ 56 Operating expenses $ 3,371 $ 3,297 $ 3,997 $ 4,560 Net loss and comprehensive loss attributable to common stockholders $ (3,198 ) $ (1,079 ) $ (5,382 ) $ (4,689 ) Net loss per common share - basic $ (0.17 ) $ (0.06 ) $ (0.28 ) $ (0.25 ) Net loss per common share - diluted $ (0.17 ) $ (0.17 ) $ (0.28 ) $ (0.25 ) Shares used in the calculation of net loss attributable to common stockholders - basic 18,902,783 18,902,783 18,902,783 18,904,280 Shares used in the calculation of net loss attributable to common stockholders - diluted 18,902,783 19,232,760 18,902,783 19,071,112 (1) Basic and diluted net loss per common share are computed independently for each of the periods presented. Accordingly, the sum of the quarterly net loss per common share amount may not agree to the total for the year.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Employment Agreements In January 2016, the Company entered into an employment agreement with Antonius Schuh, Ph.D. in which he agreed to serve as our Chief Executive Officer. The term of the agreement is effective as of January 1, 2016 and continues until January 1, 2020 and is automatically renewed for successive one year periods at the end of each term. Dr. Schuh’s base compensation is $488,800 per year. Dr. Schuh is eligible to receive an annual bonus of up to 50% of his base compensation based on meeting certain performance objectives and bonus criteria. Upon entering the agreement, Dr. Schuh was granted 450,000 non-qualified stock options which have an exercise price of $5.18 per share and vest monthly in equal amounts over a period of four years. Dr. Schuh was also granted 350,000 non-qualified stock options which have an exercise price of $5.18 per share and vested immediately upon grant. If the employment agreement is terminated by the Company without cause, Dr. Schuh is entitled to receive a severance payment equal to base compensation for twenty-four months and the potential bonus and any benefits Dr. Schuh would be eligible during such twenty-four month period. If the employment agreement is terminated as a result of a change of control, in addition to the severance payment described above, all unvested equity awards would immediately vest and become fully exercisable for a period of six months following the date of termination. In January 2016, the Company entered into an employment agreement with Stephen Zaniboni in which he agreed to serve as our Chief Financial Officer. The term of the agreement is effective as of January 1, 2016 and continues until January 1, 2020 and is automatically renewed for successive one year periods at the end to each term. Mr. Zaniboni’s base compensation is $357,500 per year. Mr. Zaniboni is eligible to receive an annual bonus of up to 50% of his base compensation based on meeting certain performance objectives and bonus criteria. Upon entering the agreement, Mr. Zaniboni was granted 150,000 non-qualified stock options which have an exercise price of $5.18 per share and vest monthly in equal amounts over a period of four years. If the employment agreement is terminated by the Company without cause, Mr. Zaniboni is entitled to receive a severance payment equal to base compensation for twelve months and the potential bonus and any benefits Mr. Zaniboni would be eligible during such twelve month period. If the employment agreement is terminated as a result of a change of control, in addition to the severance payment, all unvested equity awards would immediately vest and become fully exercisable for a period of six months following the date of termination. Debt Agreement In February 2016, the Company signed a term sheet to refinance its existing term loan entered into on June 2014. Under the term sheet, interest would be equal to 3.75% plus the Wall Street Journal Prime Rate, subject to a floor of 7.25% . Interest only payments would be for 12 months, followed by equal monthly payments of principal and interest over the following 30 months. The Company would also have an obligation to make a final payment equal to 7.50% of total funded amounts at the loan maturity date. In addition, the lenders would receive a warrant to purchase such number of shares of the Company’s common stock as is equal to 1% of the funded amount divided by an average closing price of the Company’s common stock. Registration Statement Effective February 4, 2016, the Registration Statement expired and the Company therefore will no longer be able to issue securities pursuant to the Registration Statement, including pursuant to its agreement with the Agent.

Basis of Presentation and Sum21

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of operating and money market accounts as of December 31, 2015 and 2014 on deposit with U.S. commercial banks. Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase.
Concentration of credit risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposit accounts that are not insured by the Federal Deposit Insurance Corporation in federally insured financial institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held.
Revenues	Revenues Revenue is recognized when persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured. Milestone, Royalty and License Revenues The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners. These agreements may involve multiple elements such as license fees, royalties and milestone payments. Revenue is recognized when the criteria described above have been met as well as the following: • Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured. • Minimum royalties are recognized as earned, and royalties in excess of minimum amounts are recognized upon receipt of payment when collection is assured. • Milestone payments are recognized when both the milestone is achieved and the related payment is received. Diagnostic Service Revenues Revenue for clinical laboratory tests may come from several sources, including commercial third-party payors, such as insurance companies and health maintenance organizations, government payors, such as Medicare and Medicaid in the United States, patient self-pay and, in some cases, from hospitals or referring laboratories who, in turn, might bill third-party payors for testing. The Company is recognizing diagnostic service revenue on the cash collection basis until such time as it is able to properly estimate collections on third party reimbursements.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts The Company reviews the collectability of accounts receivable based on an assessment of historic experience, current economic conditions, and other collection indicators. At each of December 31, 2015 , 2014 and 2013 , the Company had not recorded an allowance for doubtful accounts. When accounts are determined to be uncollectible, they are written off against the reserve balance and the reserve is reassessed. When payments are received on reserved accounts, they are applied to the individual’s account and the reserve is reassessed.
Derivative Financial Instruments-Warrants	Derivative Financial Instruments—Warrants The Company has issued common stock warrants in connection with the execution of certain equity financings. Such warrants are classified as derivative liabilities under the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815, Derivatives and Hedging (“ASC 815”) and are recorded at their fair market value as of each reporting period. Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1) indexed to its own stock and (2) classified in stockholders’ equity. Changes in fair value of derivative liabilities are recorded in the consolidated statement of operations under the caption “Change in fair value of derivative instruments.” The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding the volatility of Trovagene’s common stock price, the remaining life of the warrant, and the risk-free interest rates at each period end. The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value and accordingly classifies such warrants in Level 3 per FASB ASC Topic 820, Fair Value Measurements (“ASC 820”).
Stock-Based Compensation	Stock-Based Compensation FASB ASC Topic 718 “ Compensation—Stock Compensation ” (“ASC 718”) requires companies to measure the cost of employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant. The expense is recognized over the period during which an employee is required to provide services in exchange for the award. ASC 718 did not change the way Trovagene accounts for non-employee stock-based compensation. Trovagene continues to account for shares of common stock, stock options and warrants issued to non-employees based on the fair value of the stock, stock option or warrant, if that value is more reliably measurable than the fair value of the consideration or services received. The Company accounts for stock options issued and vesting to non-employees in accordance with FASB ASC Topic 505-50 “ Equity -Based Payment to Non-Employees ” , and, accordingly, the value of the stock compensation to non-employees is based upon the measurement date as determined at either (1) the date at which a performance commitment is reached, or (2) the date at which the necessary performance to earn the equity instruments is complete. Therefore, the fair value of these options is being “marked to market” quarterly until the measurement date is determined.
Fair value of financial instruments	Fair Value of Financial Instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, debt and derivative liabilities. The Company has adopted ASC 820 for financial assets and liabilities that are required to be measured at fair value and non-financial assets and liabilities that are not required to be measured at fair value on a recurring basis. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short term nature as they reflect current market interest rates. Debt is stated at its respective historical carrying amounts, which approximate fair value as they reflect current market interest rates. In accordance with FASB ASC Subtopic 820-10, the Company measures certain assets and liabilities at fair value on a recurring basis using the three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The three tiers include: • Level 1 — Quoted prices for identical instruments in active markets. • Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable. • Level 3 — Instruments where significant value drivers are unobservable to third parties.
Property, equipment and depreciation and amortization	Property, Equipment and Depreciation and Amortization Expenditures for additions, renewals and improvements are capitalized at cost. Depreciation and amortization is generally computed on a straight-line method based on the estimated useful lives of the related assets. Amortization of leasehold improvements is computed based on the shorter of the life of the asset or the term of the lease. The estimated useful lives of the major classes of depreciable assets are three to five years for laboratory equipment and furniture and fixtures. Expenditures for repairs and maintenance are charged to operations as incurred.
Impairment of Indefinite and Long-Lived Assets	Impairment of Indefinite and Long-Lived Assets The Company reviews its long-lived and indefinite assets to determine if any event has occurred that may indicate its intangible assets with indefinite lives and other long-lived assets are potentially impaired. If indicators of impairment exist, the Company performs an impairment test to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, the Company estimates the fair value of the assets and records an impairment loss if the carrying value of the assets exceeds the fair value. Factors that would indicate potential impairment include a significant decline in the Company’s stock price and market capitalization compared to its net book value, significant changes in the ability of a particular asset to generate positive cash flows, and significant changes in the Company’s strategic business objectives and utilization of a particular asset.
Income Taxes	Income Taxes Income taxes are determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes result from differences between the financial statement and tax bases of Trovagene’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment.
Contingencies	Contingencies In the normal course of business, Trovagene is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations, stockholder lawsuits, product and environmental liability, and tax matters. In accordance with FASB ASC Topic 450, Accounting for Contingencies , Trovagene records such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Trovagene, in accordance with this guidance, does not recognize gain contingencies until realized.
Cost of Revenue	Cost of Revenue Cost of revenue represents the cost of materials, personnel costs, costs associated with processing specimens including pathological review, quality control analyses, and delivery charges necessary to render an individualized test result. Costs associated with performing tests are recorded as the tests are processed.
Research and Development	Research and Development Research and development expenses, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, purchased in-process research and development and regulatory and scientific consulting fees, as well as contract research and insurance, are accounted for in accordance with FASB ASC Topic 730-10-55-2, Research and Development. Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any. While certain of the Company’s research and development costs may have future benefits, the Company’s policy of expensing all research and development expenditures is predicated on the fact that Trovagene has no history of successful commercialization of molecular diagnostic products to base any estimate of the number of future periods that would be benefited. FASB ASC Topic 730, Research and Development requires that non-refundable advance payments for goods or services that will be used or rendered for future research and development activities be deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts are recognized as an expense.
Net Loss Per Share	Net Loss Per Share Basic and diluted net loss per share is presented in conformity with FASB ASC Topic 260, Earnings per Share , for all periods presented. In accordance with this guidance, basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases . The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact the adoption of the new standard will have on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, P resentation of Financial Statements — Going Concern , which impacts the accounting guidance related to the evaluation of an entity’s ability to continue as a going concern. The amendment establishes management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern in connection with preparing financial statements for each annual and interim reporting period. The amendment also gives guidance to determine whether to disclose information about relevant conditions and events when there is substantial doubt about an entity’s ability to continue as a going concern. The amended guidance is effective prospectively for fiscal years beginning after December 15, 2016. The new guidance is not expected to have a material impact on the Company’s financial position, results of operations or cash flows. In May 2014, the FASB issued ASU 2014-9, Revenue from Contracts with Customers (“ASU 2014-9”). ASU 2014-9 provides companies with a single model for accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the model is to recognize revenue when control of the goods or services transfers to the customer, as opposed to recognizing revenue when the risks and rewards transfer to the customer under the existing revenue guidance. The guidance permits companies to either apply the requirements retrospectively to all prior periods presented, or apply the requirements in the year of adoption, through a cumulative adjustment. In August 2015, the FASB issued ASU 2015-14, Deferral of the Effective Date , which defers the required adoption date of ASU 2014-09 by one year. As a result of the deferred effective date, ASU 2014-09 will be effective for the Company in its first quarter of fiscal year 2018. Early adoption is permitted but not before the original effective date of the first quarter of fiscal year 2017. The Company is in the process of evaluating the transition method that will be elected and the impact of adoption of ASU 2014-09 on its consolidated financial statements.

Basis of Presentation and Sum22

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from the Calculation of Basic and Diluted Loss Per Share	Shares used in calculating diluted net loss per common share exclude as anti-dilutive the following share equivalents: December 31, 2015 2014 2013 Options to purchase Common Stock 6,948,630 4,913,472 4,287,545 Warrants to purchase Common stock 4,565,947 5,251,660 6,233,483 Series A Convertible Preferred Stock 63,125 63,125 63,125 11,577,702 10,228,257 10,584,153
Summary of the Company’s Diluted Net Loss Per Share	The following table summarizes the Company’s diluted net loss per share: December 31, 2015 2014 2013 Numerator: Net loss attributable to common stockholders $ (27,495,334 ) $ (14,348,499 ) $ (11,840,778 ) Adjustment for change in fair value of derivative instruments - warrants (4,396,061 ) (2,422,337 ) — Net loss used for diluted loss per share $ (31,891,395 ) $ (16,770,836 ) $ (11,840,778 ) Denominator: Weighted-average shares used to compute basic net loss per share 26,201,713 18,904,280 16,978,212 Adjustments to reflect assumed exercise of warrants 250,452 166,832 — Weighted-average shares used to compute diluted net loss per share 26,452,165 19,071,112 16,978,212 Net loss per share diluted $ (1.21 ) $ (0.88 ) $ (0.70 )

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Schedule of Components of Property and Equipment	Property and equipment consisted of the following: As of December 31, 2015 2014 Furniture and office equipment $ 1,483,227 $ 365,955 Leasehold Improvements 39,401 39,401 Laboratory equipment 2,022,733 968,901 3,545,361 1,374,257 Less—accumulated depreciation and amortization (854,782 ) (533,870 ) Property and equipment, net $ 2,690,579 $ 840,387

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Summary of Warrant Activity and Changes in Warrants Outstanding	A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications, is presented below: Number of Warrants Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Term Balance outstanding, December 31, 2012 6,985,070 $ 3.96 5.4 Granted 50,000 $ 8.00 Exercised (728,488 ) $ 4.99 Expired (73,099 ) $ 4.50 Balance outstanding, December 31, 2013 6,233,483 $ 3.87 4.5 Granted 85,470 $ 3.51 Exercised (36,666 ) $ 3.00 Expired (16,667 ) $ 10.80 Balance outstanding, December 31, 2014 6,265,620 $ 3.85 3.6 Exercised (732,378 ) $ 3.77 Balance outstanding, December 31, 2015 5,533,242 $ 3.86 2.5

Stock Option Plan (Tables)

Stock Option Plan (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock-Based Compensation Expense	Stock-based compensation has been recognized in operating results as follows: Years ended December 31, 2015 2014 2013 In cost of revenue $ 39,676 $ — $ — In research and development expenses 1,499,009 796,008 549,465 In selling and marketing expense 768,146 145,239 70,626 In general and administrative expenses 1,639,196 1,128,947 1,359,273 Total stock-based compensation $ 3,946,027 $ 2,070,194 $ 1,979,364
Schedule of Assumptions to Estimate Fair Value of Stock Option Awards	The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the years indicated below: Years ended December 31, 2015 2014 2013 Risk-free interest rate 1.35% - 2.15% 1.42% - 2.1% 0.74% - 1.5% Dividend yield 0% 0% 0% Expected volatility (range) 73% - 77% 81% - 86% 82% - 100% Expected volatility (weighted-average) 75% 85% 91% Expected term (in years) 6.0 years 5.8 years 5.0 years
Summary of Stock Option Activity of Changes in Stock Options Outstanding	A summary of stock option activity and of changes in stock options outstanding is presented below: Number of Options Weighted-Average Exercise Price Per Share Intrinsic Value Weighted-Average Remaining Contractual Life Balance outstanding, December 31, 2012 3,711,303 $ 4.69 $ 8,301,484 6.3 years Granted 1,144,760 $ 6.33 Exercised (52,500 ) $ 4.30 Forfeited (516,018 ) $ 4.35 Balance outstanding, December 31, 2013 4,287,545 $ 5.18 $ 5,896,329 6.7 years Granted 1,410,038 $ 4.42 Forfeited (784,111 ) $ 7.08 Balance outstanding, December 31, 2014 4,913,472 $ 4.66 $ 2,808,083 7.6 years Granted 2,688,500 $ 7.02 Exercised (265,166 ) $ 3.25 Forfeited (388,176 ) $ 7.75 Balance outstanding, December 31, 2015 6,948,630 $ 5.45 $ 5,903,466 7.8 years Vested and exercisable, December 31, 2015 2,825,398 $ 4.38 $ 4,194,205 6.0 years

Derivative Financial Instrume26

Derivative Financial Instruments - Warrants (Tables) - Black Scholes Option Pricing Method	12 Months Ended
	Dec. 31, 2015
Derivative financial instruments
Schedule of Assumptions Used to Determine the Fair Value of Warrants	The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was: Year ended December 31 2015 2014 2013 Estimated fair value of Trovagene common stock $5.40 - $10.15 $3.00 - $6.74 $5.74 - $7.18 Expected warrant term 3.0-3.8 years 4.0 years 1 month to 5.8 years Risk-free interest rate 0.89%-1.31% 1.38% .03%-1.75% Expected volatility 73%-77% 86.4% 82%-100% Dividend yield —% —% —%
Schedule of Components of Changes in the Company’s Derivative Financial Instruments Liability Balance	The following table sets forth the components of changes in the Company’s derivative financial instruments liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. Date Description Number of Warrants Derivative Instrument Liability December 31, 2013 Balance of derivative financial instruments liability 1,013,961 $ 4,431,871 Change in fair value of warrants during the year recognized as a gain in the statement of operations — (1,425,850 ) December 31, 2014 Balance of derivative financial instruments liability 1,013,961 3,006,021 Exercised warrants (46,666 ) (435,365 ) Change in fair value of warrants during the year recognized as a loss in the statement of operations — 726,421 December 31, 2015 Balance of derivative financial instruments liability 967,295 $ 3,297,077

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Schedule of Company’s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy	The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December 31, 2015 and 2014 : Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities Significant Other Observable Inputs Significant Unobservable Inputs Total Assets: Money market fund (1) $ 65,016,222 $ — $ — $ 65,016,222 Total Assets $ 65,016,222 $ — $ — $ 65,016,222 Liabilities: Derivative liabilities related to warrants $ — $ — $ 3,297,077 $ 3,297,077 Total Liabilities $ — $ — $ 3,297,077 $ 3,297,077 Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities Significant Other Observable Inputs Significant Unobservable Inputs Total Assets: Money market fund (1) $ 27,123,587 $ — $ — $ 27,123,587 Total Assets $ 27,123,587 $ — $ — $ 27,123,587 Liabilities: Derivative liabilities related to warrants $ — $ — $ 3,006,021 $ 3,006,021 Total Liabilities $ — $ — $ 3,006,021 $ 3,006,021 (1) Included as a component of cash and cash equivalents on the accompanying consolidated balance sheet.
Schedule of Changes in the Fair Value of the Company’s Level 3 Liabilities	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the years ended December 31, 2015 and 2014 : Description Balance at Fair Value of Warrants Reclassified to Additional Paid-in Capital Unrealized (gains) or losses Balance at Derivative liabilities related to Warrants $ 3,006,021 $ (435,365 ) $ 726,421 $ 3,297,077 Description Balance at Unrealized (gains) or losses Balance at Derivative liabilities related to Warrants $ 4,431,871 $ (1,425,850 ) $ 3,006,021

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of Future Maturities of Long-Term Debt	Future maturities of long-term debt at December 31, 2015 are as follows: 2016 $ 30,168 2017 362,021 2018 362,021 2019 331,852 Total principal 1,086,062 Plus final fee premium accretion 2,815 Total long-term obligations $ 1,088,877 Future maturities of long-term debt at December 31, 2015 are as follows: 2016 $ 5,195,650 2017 6,064,315 2018 3,740,035 Total principal 15,000,000 Less discount (151,895 ) Plus final fee premium accretion 535,024 Total long-term obligations $ 15,383,129

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Provision for Income Taxes Based on Losses from Continuing Operations	The provision for income taxes based on losses from continuing operations consists of the following at December 31 (in thousands): Years ended December 31, 2015 2014 2013 Deferred benefit Federal $ (9,602 ) $ (5,651 ) $ (3,806 ) State (1,742 ) (449 ) (593 ) Total deferred benefit (11,344 ) (6,100 ) (4,399 ) Valuation allowance 11,344 6,100 4,399 Total income tax provision $ — $ — $ —
Schedule of Significant Components of the Company’s Taxes and the Rates	Significant components of the Company’s taxes and the rates as of December 31 are shown below (in thousands, except percentages): Years ended December 31, 2015 2014 Tax computed at the federal statutory rate $ (9,340 ) 34 % $ (4,871 ) 35 % State tax, net of federal tax benefit (1,559 ) 6 % (891 ) 6 % Permanent Items 258 (1 )% (320 ) 2 % Tax credits (997 ) 3 % — — % Valuation allowance increase 11,638 (42 )% 6,081 (43 )% Other — — % 1 — % Provision for income taxes $ — — % $ — — %
Schedule of Significant Components of the Company’s Deferred Tax Assets	Significant components of the Company’s deferred tax assets and liabilities from federal and state income taxes as of December 31 are shown below: Years ended December 31, 2015 2014 Deferred tax assets Tax loss carryforwards $ 27,962,000 $ 19,010,900 Research and development credits and other tax credits 1,698,300 698,000 Stock-based compensation 3,225,200 2,193,900 Other 782,000 420,800 Total deferred tax assets 33,667,500 22,323,600 Valuation allowance (33,667,500 ) (22,323,600 ) Net deferred tax asset $ — $ —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Annual Commitments Under Current Lease Agreements	Total annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows: 2016 $ 683,871 2017 792,221 2018 811,797 2019 796,716 2020 817,989 Thereafter 842,529 Total $ 4,745,123

Selected Quarterly Financial 31

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Data [Abstract]
Summary of the Quarterly Results of Operations	The following is a summary of the quarterly results of operations of the Company for years ended December 31, 2015 and 2014 : Quarter Ended(1) March 31 June 30 September 30 December 31 (dollars in thousands, except per share data) 2015 Revenues $ 127 $ 49 $ 58 $ 79 Operating expenses $ 4,975 $ 6,682 $ 6,467 $ 7,463 Net loss and comprehensive loss attributable to common stockholders $ (7,180 ) $ (10,186 ) $ (2,742 ) $ (7,387 ) Net loss per common share - basic $ (0.33 ) $ (0.41 ) $ (0.10 ) $ (0.25 ) Net loss per common share - diluted $ (0.33 ) $ (0.41 ) $ (0.23 ) $ (0.26 ) Shares used in the calculation of net loss attributable to common stockholders - basic 21,817,710 24,592,883 28,560,211 29,723,254 Shares used in the calculation of net loss attributable to common stockholders - diluted 21,817,710 24,592,883 29,128,235 30,157,038 2014 Revenues $ 111 $ 56 $ 57 $ 56 Operating expenses $ 3,371 $ 3,297 $ 3,997 $ 4,560 Net loss and comprehensive loss attributable to common stockholders $ (3,198 ) $ (1,079 ) $ (5,382 ) $ (4,689 ) Net loss per common share - basic $ (0.17 ) $ (0.06 ) $ (0.28 ) $ (0.25 ) Net loss per common share - diluted $ (0.17 ) $ (0.17 ) $ (0.28 ) $ (0.25 ) Shares used in the calculation of net loss attributable to common stockholders - basic 18,902,783 18,902,783 18,902,783 18,904,280 Shares used in the calculation of net loss attributable to common stockholders - diluted 18,902,783 19,232,760 18,902,783 19,071,112 (1) Basic and diluted net loss per common share are computed independently for each of the periods presented. Accordingly, the sum of the quarterly net loss per common share amount may not agree to the total for the year.

Business Overview and Liquidi32

Business Overview and Liquidity (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Subsidiary, Sale of Stock [Line Items]
Cumulative net losses attributed to common stockholders	$ (108,887,243)				$ (81,391,909)				$ (108,887,243)	$ (81,391,909)
Net cash used in operating activities									22,119,025	12,727,385	$ 7,317,248
Net loss and comprehensive loss attributable to common stockholders	$ 7,387,000	$ 2,742,000	$ 10,186,000	$ 7,180,000	$ 4,689,000	$ 5,382,000	$ 1,079,000	$ 3,198,000	27,495,334	14,348,499	11,840,778
Net cash provided by financing activities									$ 64,551,740	$ 14,484,036	$ 22,983,688

Basis of Presentation and Sum33

Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Derivative financial instruments
Derivative liabilities related to warrants	$ 3,297,077	$ 3,006,021
Warrants | Black Scholes Option Pricing Method
Derivative financial instruments
Derivative liabilities related to warrants	$ 3,297,077	$ 3,006,021	$ 4,431,871

Basis of Presentation and Sum34

Basis of Presentation and Summary of Significant Accounting Policies (Details 2)	12 Months Ended
	Dec. 31, 2015
Laboratory equipment | Minimum
Property, equipment and depreciation and amortization
Estimated useful lives	3 years
Laboratory equipment | Maximum
Property, equipment and depreciation and amortization
Estimated useful lives	5 years
Furniture and fixtures | Minimum
Property, equipment and depreciation and amortization
Estimated useful lives	3 years
Furniture and fixtures | Maximum
Property, equipment and depreciation and amortization
Estimated useful lives	5 years

Basis of Presentation and Sum35

Basis of Presentation and Summary of Significant Accounting Policies (Details 3) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net Loss Per Share
Antidilutive securities excluded from computation of earnings per share (in shares)	11,577,702	10,228,257	10,584,153
Stock options
Net Loss Per Share
Antidilutive securities excluded from computation of earnings per share (in shares)	6,948,630	4,913,472	4,287,545
Warrants
Net Loss Per Share
Antidilutive securities excluded from computation of earnings per share (in shares)	4,565,947	5,251,660	6,233,483
Series A Convertible Preferred Stock
Net Loss Per Share
Antidilutive securities excluded from computation of earnings per share (in shares)	63,125	63,125	63,125

Basis of Presentation and Sum36

Basis of Presentation and Summary of Significant Accounting Policies (Details 4) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Numerator:
Net loss attributable to common stockholders	$ (7,387,000)	$ (2,742,000)	$ (10,186,000)	$ (7,180,000)	$ (4,689,000)	$ (5,382,000)	$ (1,079,000)	$ (3,198,000)	$ (27,495,334)	$ (14,348,499)	$ (11,840,778)
Adjustment for change in fair value of derivative instruments - warrants									(4,396,061)	(2,422,337)	0
Net loss used for diluted loss per share									$ (31,891,395)	$ (16,770,836)	$ (11,840,778)
Denominator:
Weighted-average shares outstanding - basic (in shares)	29,723,254	28,560,211	24,592,883	21,817,710	18,904,280	18,902,783	18,902,783	18,902,783	26,201,713	18,904,280	16,978,212
Adjustments to reflect assumed exercise of warrants (in shares)									250,452	166,832	0
Weighted-average shares used to compute diluted net loss (in shares)	30,157,038	29,128,235	24,592,883	21,817,710	19,071,112	18,902,783	19,232,760	18,902,783	26,452,165	19,071,112	16,978,212
Net loss per share diluted (in dollars per share)	$ (0.26)	$ (0.23)	$ (0.41)	$ (0.33)	$ (0.25)	$ (0.28)	$ (0.17)	$ (0.17)	$ (1.21)	$ (0.88)	$ (0.70)

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, equipment and depreciation and amortization
Depreciation and amortization	$ 378,711	$ 234,813	$ 130,520
Property and equipment, gross	3,545,361	1,374,257
Less—accumulated depreciation and amortization	(854,782)	(533,870)
Property and equipment, net	2,690,579	840,387
Furniture and office equipment
Property, equipment and depreciation and amortization
Property and equipment, gross	1,483,227	365,955
Leasehold Improvements
Property, equipment and depreciation and amortization
Property and equipment, gross	39,401	39,401
Laboratory equipment
Property, equipment and depreciation and amortization
Property and equipment, gross	$ 2,022,733	$ 968,901

Stockholders' Equity (Deficit38

Stockholders' Equity (Deficit) (Common Stock Narrative) (Details) - USD ($)	Jan. 25, 2013	Jul. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2015
Class of Stock [Line Items]
Common stock, shares issued			29,737,601	18,915,793
Proceeds from the sale of common stock			$ 61,215,399	$ 0	$ 18,829,644
Net proceeds from the sale of common stock			$ 61,215,399		$ 18,829,644
Shares issued upon exercise of warrants			732,378	36,666	728,488
Warrant exercise price of $3.00
Class of Stock [Line Items]
Exercise price of warrants (in dollars per share)					$ 3
Number of warrants exercised (in shares)					12,745
Shares issued upon exercise of warrants			449,403
Common Stock
Class of Stock [Line Items]
Aggregate stock issued during period (in shares)					3,424,605
Shares of common stock issued			9,996,531		2,631,332
Net proceeds from the sale of common stock			$ 1,000
Number of shares issued upon conversion of preferred stock into common stock					36,458
Issuance of common stock upon exercise of warrant (in shares)			282,975		715,743
Exercise price of warrants (in dollars per share)				$ 3
Stock issued during period including share-based compensation			10,821,808
Issuance of common stock upon net exercise of warrant (in shares)			277,136	13,011	7,284
Number of stock issued from stock option exercise					33,788
Issuance of common stock upon net exercise of stock option (in shares)					22,955
Issuance of common stock upon exercise of stock options (in shares)			265,166		10,833
Common Stock | Option exercise price of $4.50
Class of Stock [Line Items]
Issuance of common stock upon exercise of stock options (in shares)			265,166		41,667
Weighted average price of shares (in dollars per share)			$ 3.25		$ 4.50
Common Stock | Option exercise price, weighted average of $3.53
Class of Stock [Line Items]
Issuance of common stock upon exercise of stock options (in shares)					10,833
Weighted average price of shares (in dollars per share)					$ 3.53
Common Stock | Warrant exercise price, weighted average of $5.02
Class of Stock [Line Items]
Exercise price of warrants (in dollars per share)			$ 4.91		$ 5.02
Shares issued upon exercise of warrants			282,975
Common Stock | Warrant exercise price of $3.00
Class of Stock [Line Items]
Exercise price of warrants (in dollars per share)			$ 3.05
Issuance of common stock upon net exercise of warrant (in shares)			277,136
Public Offering and Controlled Equity Offering
Class of Stock [Line Items]
Proceeds from the sale of common stock		$ 15,000,000
Common stock, shares issued		2,142,857
Agent | Public Offering and Controlled Equity Offering
Class of Stock [Line Items]
Commission as percentage of gross proceeds	3.00%
Proceeds from the sale of common stock					$ 4,200,000
Common stock, shares issued					488,476
Secured Debt | Loan and Security Agreement
Class of Stock [Line Items]
Exercise price of warrants (in dollars per share)						$ 3.51
Maximum | Public Offering and Controlled Equity Offering
Class of Stock [Line Items]
Aggregate initial offering price	$ 150,000,000
Maximum | Agent | Public Offering and Controlled Equity Offering
Class of Stock [Line Items]
Aggregate initial offering price	$ 30,000,000
Underwritten Public Offering 2015 | Public Offering and Controlled Equity Offering | Common Stock
Class of Stock [Line Items]
Shares of common stock issued			9,711,110
Proceeds from the sale of common stock			$ 63,200,000
Price per share (in dollars per share)			$ 9.66
Underwritten Public Offering 2015 | Agent | Public Offering and Controlled Equity Offering | Common Stock
Class of Stock [Line Items]
Shares of common stock issued			285,421
Proceeds from the sale of common stock			$ 2,800,000

Stockholders' Equity (Deficit39

Stockholders' Equity (Deficit) (Schedule of Warrants) (Details 2) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Number of Warrants
Balance of warrants outstanding at the beginning of the period (in shares)	6,265,620	6,233,483	6,985,070
Granted (in shares)		85,470	50,000
Exercised (in shares)	(732,378)	(36,666)	(728,488)
Expired (in shares)		(16,667)	(73,099)
Balance of warrants outstanding at the end of the period (in shares)	5,533,242	6,265,620	6,233,483	6,985,070
Weighted-Average Exercise Price Per Share
Weighted average exercise price of warrants at the beginning of the period (in dollars per share)	$ 3.85	$ 3.87	$ 3.96
Granted (in dollars per share)		3.51	8
Exercised (in dollars per share)	3.77	3	4.99
Expired (in dollars per share)		10.80	4.50
Weighted average exercise price of warrants at the end of the period (in dollars per share)	$ 3.86	$ 3.85	$ 3.87	$ 3.96
Weighted-Average Remaining Contractual Term
Weighted-Average Remaining Contractual Term	2 years 6 months 11 days	3 years 6 months 26 days	4 years 5 months 23 days	5 years 4 months 28 days

Stockholders' Equity (Deficit40

Stockholders' Equity (Deficit) (Warrants Narrative) (Details 3) - USD ($)	1 Months Ended		12 Months Ended
	Jun. 30, 2014	Jul. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2015	Jun. 30, 2015
Class of Stock [Line Items]
Dividend yield related to stock-based compensation (as a percent)				0.00%
Fair value of warrants issued for services (in dollars)				$ 198,791
Warrants granted (in shares)			85,470	50,000
Warrants granted (in dollars per share)			$ 3.51	$ 8
Value of warrants recorded as debt discount and additional paid in capital			$ 235,857	$ 0	$ 0
Service Agreement [Member]
Class of Stock [Line Items]
Number of shares that can be purchased from exercise of warrants				50,000
Exercise price of warrants (in dollars per share)				$ 8
Term of warrants				3 years
Risk-free interest rate related to stock-based compensation (as a percent)				0.42%
Expected volatility related to stock-based compensation (as a percent)				97.00%
Expected term related to stock-based compensation				3 years
Fair value of warrants issued for services (in dollars)				$ 198,791
Public Offering and Controlled Equity Offering
Class of Stock [Line Items]
Proceeds from the sale of common stock		$ 15,000,000
Secured Debt
Class of Stock [Line Items]
Number of shares that can be purchased from exercise of warrants					42,735
Line of Credit | Secured Debt
Class of Stock [Line Items]
Number of shares that can be purchased from exercise of warrants						85,470
Exercise price of warrants (in dollars per share)						$ 3.51
Value of warrants recorded as debt discount and additional paid in capital	$ 235,857
Line of Credit | Secured Debt | Black Scholes Option Pricing Method
Class of Stock [Line Items]
Risk-free interest rate (as a percent)	2.53%
Dividend yield (as a percent)	0.00%
Expected volatility (as a percent)	73.80%
Expected warrant term	10 years

Stockholders' Equity (Deficit41

Stockholders' Equity (Deficit) (Preferred Stock) (Details 4) - USD ($)	Mar. 17, 2007	Jul. 13, 2006	Mar. 17, 2006	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accrued dividend during the period				$ 24,240	$ 23,015	$ 29,840
Stated value per share (in dollars per share)				$ 0.001	$ 0.001
Number of shares outstanding				60,600	60,600
Deficit Accumulated
Accrued dividend during the period				$ 24,240	$ 23,015	29,840
Series A Convertible Preferred Stock
Cumulative dividend rate (as a percent)				4.00%
Accrued cumulative unpaid preferred stock dividends				$ 268,295	$ 244,055	$ 221,040
Stated value per share (in dollars per share)				$ 10
Conversion price per share (in dollars per share)	$ 9.60		$ 2.15
Period during which the conversion price is subject to adjustment for dilutive issuances			12 months
Share price for 20 consecutive trading days for automatic conversion		$ 25.80
Number of consecutive trading days in which the closing price of the entity's common stock must equal or exceed a specified price in order for the preferred stock to be automatically converted		20 days
Number of common stock shares traded per day during the 20 trading days for the preferred stock to be automatically converted		8,333
Number of trading days in which the specified volume of common stock must be traded for the preferred stock to be automatically converted		20 days
Number of shares converted						35,000
Number of shares issued upon conversion of preferred stock into common stock						36,458
Number of shares outstanding				60,600	60,600	60,600

Stock Option Plan (Details)

Stock Option Plan (Details) - USD ($)	Jun. 10, 2015	Jul. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Sep. 17, 2014	Jul. 18, 2013	Jul. 17, 2013
Stock Options
Intrinsic value of options exercised			$ 1,382,255	$ 0	$ 275,492
Fair value of shares vested			$ 2,634,688	$ 1,960,256	$ 1,633,071
2014 EIP
Stock Options
Number of authorized shares under the plan						2,500,000
Number of remaining shares available for issuance			1,361,832
Equity Incentive Plan 2014
Stock Options
Number of additional shares authorized (in shares)	2,500,000
Stock options
Stock Options
Number of shares of common stock granted			2,688,500	1,410,038	1,144,760
Stock options | 2004 Plan
Stock Options
Number of authorized shares under the plan							6,000,000	3,666,667
Expiration term of options			10 years
Number of remaining shares available for issuance					1,788,921
Number of options issued over the authorized number of options in the Plan (in shares)					260,000
Option overage liability							$ 23,024
Stock options | Minimum | 2004 Plan
Stock Options
Vesting period of options			3 years
Stock options | Maximum | 2004 Plan
Stock Options
Vesting period of options			4 years
Board of Directors | Stock options | 2004 Plan
Stock Options
Number of shares of common stock granted		90,000
Fair value of option granted		$ 500,000

Stock Option Plan (Details 2)

Stock Option Plan (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Stock-based compensation expense
Total stock based compensation expense	$ 3,946,027	$ 2,070,194	$ 1,979,364
Cost of Sales [Member]
Stock-based compensation expense
Total stock based compensation expense	39,676	0	0
Research and Development Expense [Member]
Stock-based compensation expense
Total stock based compensation expense	1,499,009	796,008	549,465
Selling and Marketing Expense [Member]
Stock-based compensation expense
Total stock based compensation expense	768,146	145,239	70,626
General and Administrative Expense [Member]
Stock-based compensation expense
Total stock based compensation expense	$ 1,639,196	$ 1,128,947	$ 1,359,273

Stock Option Plan (Details 3)

Stock Option Plan (Details 3) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Intrinsic Value
Intrinsic value of options exercised	$ 1,382,255	$ 0	$ 275,492
Tax benefits recognized	$ 0
Stock options
Stock Options
Weighted average grant date fair value (in dollars per share)	$ 4.60	$ 3.16	$ 4.54
Unrecognized compensation cost
Unrecognized compensation cost	$ 10,430,604	$ 4,862,030
Weighted-average remaining vesting period for recognition	3 years 1 month 6 days	3 years
Weighted-average assumptions
Dividend yield	0.00%	0.00%	0.00%
Expected volatility (weighted-average)	75.00%	85.00%	91.00%
Expected term (in years)	6 years 16 days	5 years 9 months 18 days	5 years
Number of Options
Balance outstanding	4,913,472	4,287,545	3,711,303
Granted (in shares)	2,688,500	1,410,038	1,144,760
Exercised (in shares)	(265,166)		(52,500)
Forfeited (in shares)	(388,176)	(784,111)	(516,018)
Balance outstanding	6,948,630	4,913,472	4,287,545	3,711,303
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	2,825,398
Weighted-Average Exercise Price Per Share
Balance outstanding at the beginning of the period (in dollars per share)	$ 4.66	$ 5.18	$ 4.69
Granted (in dollars per share)	7.02	4.42	6.33
Exercised (in dollars per share)	3.25		4.30
Forfeited (in dollars per share)	7.75	7.08	4.35
Balance outstanding at the end of the period (in dollars per share)	5.45	$ 4.66	$ 5.18	$ 4.69
Vested and exercisable at the end of the period (in dollars per share)	$ 4.38
Intrinsic Value
Intrinsic value of options outstanding	$ 5,903,466	$ 2,808,083	$ 5,896,329	$ 8,301,484
Vested and Exercisable at the end of the period, Intrinsic Value	$ 4,194,205
Weighted Average Remaining Contractual Life	7 years 9 months 11 days	7 years 7 months 6 days	6 years 8 months 12 days	6 years 3 months 18 days
Weighted average life vested and exercisable	6 years 17 days
Stock options | Minimum
Weighted-average assumptions
Risk-free interest rate	1.35%	1.42%	0.74%
Expected volatility (range)	73.00%	81.00%	82.00%
Stock options | Maximum
Weighted-average assumptions
Risk-free interest rate	2.15%	2.10%	1.50%
Expected volatility (range)	77.00%	86.00%	100.00%

Derivative Financial Instrume45

Derivative Financial Instruments - Warrants (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Changes in the Company's derivative financial instruments liability balance
Balance of warrants outstanding at the beginning of the period (in shares)	6,265,620	6,233,483	6,985,070
Exercised (in shares)	(732,378)	(36,666)	(728,488)
Balance of warrants outstanding at the end of the period (in shares)	5,533,242	6,265,620	6,233,483
Balance of derivative financial instruments liability at the beginning of the period	$ 3,006,021
Change in fair value of warrants during the period recognized as a gain in the condensed consolidated statement of operations	726,421	$ (1,425,850)	$ 1,084,114
Decrease in derivative liability due to exercise of warrants	(435,365)
Balance of derivative financial instruments liability at the end of the period	$ 3,297,077	$ 3,006,021
Warrants
Changes in the Company's derivative financial instruments liability balance
Weighted average remaining contractual life	2 years 6 months 11 days	3 years 7 months 6 days
Warrants | Black Scholes Option Pricing Method
Range of assumptions used to determine the fair value of warrants
Dividend yield (as a percent)	0.00%	0.00%	0.00%
Changes in the Company's derivative financial instruments liability balance
Balance of warrants outstanding at the beginning of the period (in shares)	1,013,961	1,013,961
Exercised (in shares)	(46,666)
Balance of warrants outstanding at the end of the period (in shares)	967,295	1,013,961	1,013,961
Balance of derivative financial instruments liability at the beginning of the period	$ 3,006,021	$ 4,431,871
Change in fair value of warrants during the period recognized as a gain in the condensed consolidated statement of operations	726,421	(1,425,850)
Balance of derivative financial instruments liability at the end of the period	$ 3,297,077	$ 3,006,021	$ 4,431,871
Warrants | Black Scholes Option Pricing Method | Minimum
Range of assumptions used to determine the fair value of warrants
Estimated fair value of Trovagene common stock (in dollars per share)	$ 5.40	$ 3	$ 5.74
Expected warrant term	3 years	4 years	1 month 6 days
Risk-free interest rate (as a percent)	0.89%	1.38%	0.03%
Expected volatility (as a percent)	73.00%	86.40%	82.00%
Warrants | Black Scholes Option Pricing Method | Maximum
Range of assumptions used to determine the fair value of warrants
Estimated fair value of Trovagene common stock (in dollars per share)	$ 10.15	$ 6.74	$ 7.18
Expected warrant term	3 years 9 months	4 years	5 years 9 months 18 days
Risk-free interest rate (as a percent)	1.31%	1.38%	1.75%
Expected volatility (as a percent)	77.00%	86.40%	100.00%

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Liabilities:
Derivative liabilities related to warrants	$ 3,297,077	$ 3,006,021
Recurring basis | Estimate of Fair Value Measurement
Assets:
Money market fund	65,016,222	27,123,587
Total Assets	65,016,222	27,123,587
Liabilities:
Derivative liabilities related to warrants	3,297,077	3,006,021
Total Liabilities	3,297,077	3,006,021
Recurring basis | Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)
Assets:
Money market fund	65,016,222	27,123,587
Total Assets	65,016,222	27,123,587
Recurring basis | Significant Unobservable Inputs (Level 3)
Liabilities:
Derivative liabilities related to warrants	3,297,077	3,006,021
Total Liabilities	$ 3,297,077	$ 3,006,021

Fair Value Measurements (Deta47

Fair Value Measurements (Details 2) - Warrants - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Reconciliation of the beginning and ending balances
Balance at the beginning of the period	$ 3,006,021	$ 4,431,871
Fair Value of Warrants Reclassified to Additional Paid-in Capital	(435,365)
Unrealized (gains) or losses	726,421	(1,425,850)
Balance at the end of the period	$ 3,297,077	$ 3,006,021

Debt - Equipment Line of Credit

Debt - Equipment Line of Credit (Details) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 30, 2015	Dec. 31, 2015
Line of Credit Facility [Line Items]
Long-term line of credit		$ 1,086,062
Amounts due under current line of credit		30,168
Long-term liabilities		1,058,709
Line of Credit
Line of Credit Facility [Line Items]
Maximum borrowing capacity for line of credit	$ 2,000,000
Line of credit facility period for principal and interest payments after date of advance	36 months
Repayment of total amounts borrowed as a percent	7.00%
Accrued interest		2,815
Interest expenses recorded		5,702
Long-term Debt, Fiscal Year Maturity [Abstract]
2,016		30,168
2,017		362,021
2,018		362,021
2,019		331,852
Total principal		1,086,062
Plus final fee premium accretion		2,815
Total long-term obligations		$ 1,088,877
Prime Rate | Line of Credit
Line of Credit Facility [Line Items]
Interest rate above reference rate	1.25%

Debt - Loan and Security Agreem

Debt - Loan and Security Agreement (Details 2)	1 Months Ended		12 Months Ended
	Jun. 30, 2015USD ($)intangible_asset$ / sharesshares	Jun. 30, 2014USD ($)	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Debt
Threshold of unrestricted net cash proceeds required to extend interest only payment date	$ 30,000,000
Threshold level of unrestricted net cash proceeds required to extend interest only payment date after amendment	$ 21,000,000
Term of extension for interest only payment			6 months
Value of warrants recorded as debt discount and additional paid in capital			$ 0	$ 235,857	$ 0
Current portion of long-term debt			5,225,818	1,898,548
Amount borrow, long-term liabilities			$ 11,246,188	$ 13,053,117
Secured Debt
Debt
Number of common shares that can be purchased upon exercise of warrant | shares			42,735
Loan and Security Agreement
Debt
Accrued interest			$ 2,815
Future maturities of long-term debt
2,016			30,168
2,017			362,021
2,018			362,021
Total principal			1,086,062
Plus final fee premium accretion			2,815
Total long-term obligations			1,088,877
Interest expenses recorded			5,702
Loan and Security Agreement | Secured Debt
Debt
Face value of term loan		$ 15,000,000
Number of banks with which agreement is entered | intangible_asset	2
Interest rate (as a percent)	7.07%
Number of common shares that can be purchased upon exercise of warrant | shares	85,470
Exercise price of warrants (in dollars per share) | $ / shares	$ 3.51
Exercisable term		10 years
Value of warrants recorded as debt discount and additional paid in capital		$ 235,857
Amortized portion of final fee upon repayment			1,050,000
Current portion of long-term debt			5,195,650
Amount borrow, long-term liabilities			10,187,479
Accrued interest			535,024
Future maturities of long-term debt
2,016			5,195,650
2,017			6,064,315
2,018			3,740,035
Total principal			15,000,000
Less discount			(151,895)
Plus final fee premium accretion			535,024
Total long-term obligations			15,383,129
Interest expenses recorded			$ 1,590,750
Loan and Security Agreement | Secured Debt | Minimum
Debt
Pre-payment fees (as a percent)			1.00%
Loan and Security Agreement | Secured Debt | Maximum
Debt
Pre-payment fees (as a percent)			3.00%

Income Taxes (Details)

Income Taxes (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Operating loss carryforwards (NOLs)
Interest and/or penalties incurred	$ 0
Federal
Operating loss carryforwards (NOLs)
NOLs	72,600,000
California
Operating loss carryforwards (NOLs)
NOLs	52,600,000
New Jersey
Operating loss carryforwards (NOLs)
NOLs	6,900,000
R&D credits | Federal
Operating loss carryforwards (NOLs)
Tax credits	1,200,000
R&D credits | California Franchise Tax Board [Member]
Operating loss carryforwards (NOLs)
Tax credits	$ 500,000

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Deferred benefit
Federal	$ (9,602)	$ (5,651)	$ (3,806)
State	(1,742)	(449)	(593)
Total deferred benefit	(11,344)	(6,100)	(4,399)
Valuation allowance	11,344	6,100	4,399
Total income tax provision	$ 0	$ 0	$ 0

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Tax computed at the federal statutory rate	$ (9,340)	$ (4,871)
State tax, net of federal tax benefit	(1,559)	(891)
Permanent Items	258	(320)
Tax credits	(997)	0
Valuation allowance increase	11,638	6,081
Other	0	1
Provision for income taxes	$ 0	$ 0	$ 0
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Tax computed at the federal statutory rate (as a percent)	34.00%	35.00%
State tax, net of federal tax benefit (as a percent)	6.00%	6.00%
Permanent Items (as a percent)	(1.00%)	2.00%
Tax credits (as a percent)	3.00%	(0.00%)
Valuation allowance increase (decrease) (as a percent)	(42.00%)	(43.00%)
Other (as a percent)	0.00%	0.00%
Provision for income taxes (as a percent)	0.00%	0.00%

Income Taxes (Details 3)

Income Taxes (Details 3) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets
Tax loss carryforwards	$ 27,962,000	$ 19,010,900
Research and development credits and other tax credits	1,698,300	698,000
Stock-based compensation	3,225,200	2,193,900
Other	782,000	420,800
Total deferred tax assets	33,667,500	22,323,600
Valuation allowance	(33,667,500)	(22,323,600)
Net deferred tax asset	$ 0	$ 0

Commitments and Contingencies54

Commitments and Contingencies (Details)	Jun. 11, 2015USD ($)ft²	Nov. 30, 2015USD ($)ft²	Dec. 31, 2015USD ($)$ / shares	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Other Commitments [Line Items]
Square footage of leased space | ft²	22,600	2,300
Monthly lease rent	$ 60,000	$ 3,100
Rent expense			$ 471,000	$ 315,000	$ 294,000
Lease period		3 years
Research and Development Expense [Member]
Other Commitments [Line Items]
Expense related to services provided by collaborators			$ 1,362,000	$ 712,000	$ 217,000
Deferred Bonus | Management [Member]
Other Commitments [Line Items]
Minimum measurement period of stock price			90 months
Minimum share price for bonus (in dollars per share) | $ / shares			$ 7.50
Contingent bonus awarded			$ 3,500,000
Bonus amount as a percentage of enterprise value			4.00%

Commitments and Contingencies55

Commitments and Contingencies (Details 2)	Dec. 31, 2015USD ($)
Total annual commitments under current lease agreements
2,016	$ 683,871
2,017	792,221
2,018	811,797
2,019	796,716
2,020	817,989
Thereafter	842,529
Total	$ 4,745,123

Employee Benefit Plan (Details)

Employee Benefit Plan (Details)	12 Months Ended
	Dec. 31, 2015
Defined Contribution Plan
Threshold age to be eligible to make catch-up contributions to the plan per IRS code	50 years

Related Party Transactions (Det

Related Party Transactions (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Board of Directors Chairman [Member]
Related Party Transaction [Line Items]
Length of contract	1 year
Per month commitment amount	$ 9,500
Scientific Advisory Board Member [Member]
Related Party Transaction [Line Items]
Research and development expense	188,000
Maximum commitment for related party services	529,000
Royalty expense	0
541690 Other Scientific and Technical Consulting Services [Member] | Board of Directors Chairman [Member]
Related Party Transaction [Line Items]
Research and development expense	$ 114,000

Selected Quarterly Financial 58

Selected Quarterly Financial Data (Unaudited) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Data [Abstract]
Revenues	$ 79,000	$ 58,000	$ 49,000	$ 127,000	$ 56,000	$ 57,000	$ 56,000	$ 111,000	$ 312,812	$ 280,178	$ 259,246
Operating expenses	7,463,000	6,467,000	6,682,000	4,975,000	4,560,000	3,997,000	3,297,000	3,371,000	25,586,464	15,225,337	10,949,787
Net loss and comprehensive loss attributable to common stockholders	$ (7,387,000)	$ (2,742,000)	$ (10,186,000)	$ (7,180,000)	$ (4,689,000)	$ (5,382,000)	$ (1,079,000)	$ (3,198,000)	$ (27,495,334)	$ (14,348,499)	$ (11,840,778)
Net loss per common share - basic (in dollars per share)	$ (0.25)	$ (0.10)	$ (0.41)	$ (0.33)	$ (0.25)	$ (0.28)	$ (0.06)	$ (0.17)	$ (1.05)	$ (0.76)	$ (0.70)
Net loss per common share - diluted (in dollars per share)	$ (0.26)	$ (0.23)	$ (0.41)	$ (0.33)	$ (0.25)	$ (0.28)	$ (0.17)	$ (0.17)	$ (1.21)	$ (0.88)	$ (0.70)
Shares used in the calculation of net loss attributable to common stockholders - basic	29,723,254	28,560,211	24,592,883	21,817,710	18,904,280	18,902,783	18,902,783	18,902,783	26,201,713	18,904,280	16,978,212
Shares used in the calculation of net loss attributable to common stockholders - diluted	30,157,038	29,128,235	24,592,883	21,817,710	19,071,112	18,902,783	19,232,760	18,902,783	26,452,165	19,071,112	16,978,212

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	1 Months Ended			12 Months Ended
	Feb. 29, 2016	Jan. 31, 2016	Nov. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2015
Stock options
Subsequent Event [Line Items]
Number of options granted (in shares)				2,688,500	1,410,038	1,144,760
Chief Executive Officer | Subsequent Event
Subsequent Event [Line Items]
Base compensation		$ 488,800
Percentage of base compensation		50.00%
Severance payment period		24 months
Period following termination that options become vested and exercisable		6 months
Chief Executive Officer | Stock options | Subsequent Event
Subsequent Event [Line Items]
Vesting period of options		4 years
Chief Financial Officer | Subsequent Event
Subsequent Event [Line Items]
Base compensation		$ 357,500
Percentage of base compensation		50.00%
Number of options granted (in shares)		150,000
Exercise price (in dollars per share)		$ 5.18
Severance payment period		12 months
Period following termination that options become vested and exercisable		6 months
Term of agreement		1 year
Chief Financial Officer | Stock options | Subsequent Event
Subsequent Event [Line Items]
Vesting period of options		4 years
Line of Credit | Secured Debt
Subsequent Event [Line Items]
Interest rate floor (as a percent)							7.07%
Line of Credit | Secured Debt | Subsequent Event
Subsequent Event [Line Items]
Final payment as a percentage of amount borrowed		7.50%
Interest only payment period	12 months
Interest and principal payment period	30 months
Percentage of funded amount divided by average closing price from warrant to purchase common stock		1.00%
Minimum | Line of Credit | Secured Debt | Subsequent Event
Subsequent Event [Line Items]
Interest rate floor (as a percent)		7.25%
Prime Rate | Line of Credit
Subsequent Event [Line Items]
Interest rate above reference rate			1.25%
Prime Rate | Line of Credit | Secured Debt | Subsequent Event
Subsequent Event [Line Items]
Interest rate above reference rate		3.75%
Vesting Over Four Years | Chief Executive Officer | Subsequent Event
Subsequent Event [Line Items]
Number of options granted (in shares)		450,000
Exercise price (in dollars per share)		$ 5.18
Vest Upon Grant | Chief Executive Officer | Subsequent Event
Subsequent Event [Line Items]
Number of options granted (in shares)		350,000
Exercise price (in dollars per share)		$ 5.18